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CHAPTER ONE
INTRODUCTION
Each year, approximately 69 million individuals across the world sustain a
traumatic brain injury (TBI)1. The incidence of TBI around the world is often referred to
as a ‘silent epidemic’, as the injury occurs internally and remains invisible to everyone
aside from the victim1,2. TBIs can occur in any age group, ethnicity, geographical region,
gender, or other major demographic. Everyone is at risk of sustaining a TBI, so
precaution and prevention are crucial. TBIs result in debilitating symptoms and poor
health outcomes that can worsen and persist over time. Regardless of severity, even a
single mild TBI (mTBI) can lead to a multitude of physical, cognitive, and behavioral
symptoms. Even more, repeat mild TBI (rmTBI) can lead to a host of symptoms that
worsen with each injury. The exacerbation of symptoms after each mTBI can occur nonlinearly. Each subsequent mTBI can result in symptoms that exponentially worsen. For
example, a third mTBI can result in much more severe vestibular deficits than the
occurrence of symptoms between the first and second mTBI. It is for this reason that
immediate diagnosis and treatment is paramount to obtain the best possible health
outcome and to prevent further injury.
One prevalent emotional symptom following rmTBI is anxiety3. The development
of anxiety can be crippling for the individual; however, it is also a symptom that often
goes undiagnosed due to a lack of desire to seek treatment4. The primary goal of this
thesis was to identify whether anxiety-like behaviors increased after rmTBI. Anxiety has
1
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long been associated with the amygdala, as a brain region involved in fear and
emotional processing5. Less studied, however, is the role that TBI and, specifically,
rmTBI plays in the development of anxiety. For this reason, the medial amygdaloid
nucleus was chosen to study in this project as a key region involved within the anxiety
neurocircuitry. In order to study the effects of rmTBI on anxiety, a five-hit rmTBI
experimental rat model was utilized. Through this model, anxiety-like behaviors could be
observed and then the brains of rats that have endured repetitive hits could be
investigated. The results of this thesis could provide more insight into the development
and persistence of anxiety, as well as could help pinpoint a brain region that could be
involved in anxiety progression.
After anxiety-like behaviors were identified following rmTBI, the next step in this
thesis was to determine whether a therapy could be utilized to reduce or even eliminate
acute and/or persistent anxiety-like behaviors. The second goal of this thesis was to
identify whether a gonadal steroid treatment after rmTBI could effectively reduce
anxiety-like behaviors or be neurotherapeutic. The gonadal steroid utilized within this
treatment was the androgen, testosterone. Testosterone has been shown to be
suppressed after even a single TBI6, so restoring testosterone to a physiological level
within that individual could be critical. Since testosterone has been shown to be
anxiolytic, it was an obvious choice as a potential neurotherapeutic or treatment6-8.
Another impactful effect that testosterone has within the body is in its ability to
alleviate oxidative stress within various cell types9,10. The medial amygdaloid nucleus,
as a subpopulation of cells within the amygdala, may be exposed to oxidative stress
which could lead to mitochondrial dysfunction. Oxidative stress and mitochondrial
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dysfunction can eventually lead to cell death when the cell becomes overwhelmed by
the oxidative load. rmTBI could cause mitochondrial dysfunction within this brain region
which could lead to anxiety. Therefore, the hypothesis tested in this thesis is that
treatment with testosterone could reduce oxidative stress that occurs within the medial
amygdaloid nucleus after rmTBI and subsequently reduce anxiety-like behaviors as a
result.
The prevalence of rmTBI across the world demands attention and calls for further
preventative measures to be taken. Data collected, analyzed, and disseminated from
TBI research not only provides more awareness of this epidemic, but it encourages
individuals to seek medical attention by a licensed medical professional following injury.
This information also fosters the development of new screening methods, therapies,
and even potential treatments.
Significance Statement
Individuals sustaining rmTBIs could subsequently suffer from worsening
emotional deficits and psychiatric disorders due to persistently low levels of gonadal
steroids. These disorders include generalized anxiety, Post-traumatic stress disorder
(PTSD), depression, and many others that lower quality of life and lead to a variety of
health complications. These complications, such as heart disease, can even lead to
death. This thesis proposal addresses the TBI public health concern and provides
further insight into how anxiety-like behaviors are exacerbated by hypogonadism after
rmTBI as a result of mitochondrial dysfunction in the medial amygdaloid nucleus.

CHAPTER TWO
LITERATURE REVIEW AND BACKGROUND
Traumatic Brain Injury
The Centers for Disease Control and Prevention (CDC) reported nearly 2.7
million TBI-related emergency room visits in the US in 2014 alone11. Over 56,000
deaths were attributed to TBI that year. Despite millions of TBIs that are treated
annually, there are likely many more cases that go unreported by individuals who chose
not to seek medical diagnosis or treatment12. A mTBI, also known as a “concussion”, is
the result of a bump, blow, or jolt to the head that disrupts normal brain function and can
result in a temporary loss or alternation of consciousness13. The vast majority, between
70-90%, of TBIs that occur annually are of mild severity14,15, and while many patients
recover fully, some will continue to experience lasting, debilitating symptoms. mTBIs
lead to physical, cognitive, emotional, and/or behavioral symptoms that can last for
days, months, or years beyond the time of injury. There are two major components at
play after an individual endures a mTBI and the subsequent physiological response,
known as the primary injury and secondary injury. The primary injury, or the direct,
immediate injury is the result of the initial impact by an external force on brain tissue
through direct mechanical forces16. The secondary injury, or the indirect, delayed injury
is the result of physiological stress in the brain tissue triggered by the primary injury
after a period of time, after seconds, minutes, days, or weeks have passed since the
initial blow.
4
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Examples of secondary injuries are hematomas, contusion, edema, chronic
inflammation, etc11.
Populations at Risk of mTBI
mTBIs are a significant public health concern and can affect any individual or
population in the United States. Some have called mTBIs a ‘silent epidemic’ since many
symptoms and impairments that result (i.e. memory impairments) are not visible17.
Several vulnerable populations at increased risk of sustaining mTBIs include athletes
that endure sports-related injuries, the elderly, children, active military service members
and veterans, and victims of domestic abuse. Risk is referred to as the chance or
likelihood that an event will occur within a given amount of time. In terms of overall
numbers of TBIs that occur annually, it was reported that between 1.6 to 3.8 million
concussions occur in sports and other recreational activities annually15. The greatest
incidence of sports-related concussions is those sustained in football18. Incidence is
defined as the number of first occurrences of an event in a population within a given
amount of time, whereas prevalence would refer to the total number of occurrences of
an event in a population within a given amount of time, usually given as a percentage of
that population19. Risk and prevalence are similar in that they can each provide
information about the likelihood of an event occurring within the overall population, such
as the United States. The statistic provided for sports and recreational activities
demonstrates that, of all sports-related TBIs, football accounts for the greatest incidence
of TBIs within that category each year. The CDC identified falls as the leading cause of
TBIs in 201413. Falls accounted for nearly half of all TBI-related emergency room visits
that year. Children and older adults experience a disproportionate number of falls
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compared to other populations with high risk. Nearly half of TBI-related emergency
room visits were from falls in children, and four out of five emergency room visits were
from falls in adults ages 65 and older13,20. Another population that has largely been
overlooked in mTBI research include victims of domestic abuse. Physical injuries, such
as repeated blows to the head by domestic partners or falls as a result of these blows
can lead to mTBIs and increased negative health outcomes in those affected21. One
study reported that between 44-75% of women experiencing intimate-partner violence
have sustained repetitive mTBIs from their domestic partners, or abusers22.
Repeat mTBI
Sustaining a single mTBI increases the risk of incurring another by 200-500%
and is associated with higher likelihood of persistent symptoms and long-term
dysfunction23. Thus, athletes or active military members who ‘return-to-play’ or ‘returnto-duty’, respectively, after sustaining a mTBI without proper recovery time are at
greater risk of subsequent TBI15. Both clinical studies and experimental animal models
of rmTBI have pointed to an increased vulnerability for behavioral, cognitive, metabolic,
and motor impairments, as well as increased risk of developing long-term
neurodegenerative diseases24. Sustained rmTBIs have also been associated with the
development of chronic traumatic encephalopathy, which is a neurodegenerative
disease diagnosed by detection of tauopathy and atrophy of the cerebrum due to
accumulation of hyper-phosphorylated tau protein and aggregated neurofibrillary
tangles25.
When a TBI is sustained, there are two major sites where primary injury occurs
on the brain in respect to the skull. The brain is positioned within the skull where it is
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suspended in cerebral spinal fluid. The first site of injury, also known as the coup injury,
is the initial site after impact. For example, in a direct impact injury, an individual falls
into or is struck by a fixed object. The brain is forced into the skull, ipsilateral to site of
injury. After this coup injury, if the head can rotate freely in space, the brain then recoils
away from the side of the skull ipsilateral to injury and impacts the contralateral side of
the skull. This is referred to as the contrecoup injury. Each of these injuries, ipsilateral
and contralateral to site of initial impact, are considered the primary injury.
Various animal models have been developed to examine the mechanistic links
between rmTBI and psychological and neurodegenerative pathology. These models of
rmTBI utilized in the field include fluid percussion26, closed-headed closed cortical
impactor (CCI) device25,26, open-headed CCI25, weight drop26, and blast injury26. Studies
in this thesis utilized the closed-headed CCI device, as it best represented rmTBI
clinically and allowed for free rotation of the head and subsequent contrecoup of the
brain from impact. Other models require a craniotomy, metal bars that keep the head in
position, an energy wave, or a weight dropped on the head, while the closed-headed
CCI model more accurately represents individuals sustaining a mTBI in regular, day-today life.
Hypogonadism following mTBI
It has been reported that 15-68% of TBI survivors experience deficiencies in
pituitary hormones, with 35-50% meeting criteria for at least one neuroendocrine
dysfunction27. Hypogonadism, or depressed endogenous testosterone levels, occurs
acutely in just about every patient following a TBI28. As many as 80% of men
experienced hypogonadism following a severe TBI29. While many patients recover their

8
gonadal status within days or weeks following a mTBI, as many as 41% continue to
suffer from chronic hypogonadism, with endogenous testosterone levels that do not
return to baseline, pre-injury levels even months or years post-injury30. Gonadotropinreleasing hormone released by the hypothalamus, as well as follicle-stimulating
hormone and luteinizing hormone released by the anterior pituitary, are altered in
humans after mTBI31. Women also undergo changes in gonadal steroid production
following TBI. As many as 46% experience amenorrhea for up to 60 months post-TBI32.
Several studies have shown that, while chronic hypogonadism in the general population
likely lies between 25-40%33, prevalence is likely between 40-80% in military
populations that have received a TBI34. However, the exact location of dysfunction that
results in altered hormone levels remains unknown. This dysfunction due to TBI could
occur at the level of the hypothalamus, the pituitary gland, or it could occur somewhere
else along the hypophyseal portal vasculature that connects the hypothalamus to the
anterior pituitary gland. Another possibility is diffuse edema in the brain that could affect
multiple brain regions.
Anxiety Disorders and TBI
Anxiety disorders are common in the general population of the United States and
are divided into different categories based on presentation of symptoms. PTSD,
generalized anxiety disorder, panic disorder, obsessive compulsive disorder, and other
phobia-specific anxiety disorders make up common diagnoses and are even more
prevalent following TBI35. The prevalence of TBI-related psychiatric disorders, in
accordance with the DSM-IV, is listed in Table 1 below. In this table, PTSD is the
second most common anxiety disorder diagnosed post-TBI, behind ‘anxiety disorders,
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not otherwise specified’ . The ‘anxiety disorders, not otherwise specified’ diagnostic
determination in this table was used to represent symptoms that fail to meet essential
criteria to be considered a specific anxiety disorder.
Although anxiety is one of the most common and prominent deficits that develops
post-TBI35, two-thirds of Americans will fail to seek treatment for their anxiety disorder36.
Approximately 10-34% of the U.S. population is diagnosed with anxiety following a
TBI35. It was also reported that 44% of U.S. soldiers that returned from Iraq and
Afghanistan after they sustained a TBI met criteria for a positive PTSD diagnosis37.
Proper diagnosis of PTSD remains a challenge due to considerable overlap of
symptoms or non-specific symptomology between PTSD and TBI, which include mood
and anxiety symptoms38. Patients with PTSD or TBI often present with nonspecific
symptoms that include generalized anxiety, memory issues, irritability, etc., further
complicating accurate diagnosis and treatment39.
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Table 1. Prevalence of TBI-related Psychiatric Disorders. DSM-IV psychiatric
disorders of interest, diagnosed pre- and 12 months post-TBI, have been listed in this
table. Anxiety disorders have been identified and include the first and second most
common 12-month post-TBI diagnoses, ‘Anxiety disorder not otherwise specified’ and
‘PTSD’. (Table modified from Ponsford et al., 2018)

Disorder
Any disorder
Any mood
disorder
Any anxiety
disorder
Major depressive
PTSD
Generalized
anxiety disorder
Anxiety disorder,
not otherwise
specified
Substance use
disorder

Pre-TBI
(%)
52.9
23.5

Post-TBI
(%)
60.9
42.2

21.6

44.1

13.7
2.0
1.0

29.4
12.7
2.0

5.9

35.3

34.3

11.8

Brain Regions Involved in Anxiety
Dysfunction within the amygdala, prefrontal cortex, hippocampus, and the
hypothalamus have been linked to the pathophysiology of anxiety disorders and
development of PTSD40. Upon receiving sensory input from the environment through
the medial prefrontal cortex, the basolateral amygdala integrates and sends this
information to the central amygdala for further processing before it leaves the
amygdala41. One particular region of interest for this thesis is the medial amygdaloid
nucleus. This area has been shown to contribute to various social behaviors, including
approach-avoidance behaviors42, stress responsivity43, and other behaviors related to
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fear and anxiety. However, this area has not been well studied within individuals that
have suffered rmTBIs.
The amygdala is known to trigger defensive responses through neuronal
projections to regions such as the bed nucleus of the stria terminalis (BNST), ventral
tegmental area, hypothalamus, hippocampus, and orbitofrontal cortex41. Brain
structures such as the amygdala and hippocampus have been well studied in anxiety
research and are linked to fear learning processes. Another key region that remains
central to the anxiety circuitry in the brain is the BNST44. The BNST has been implicated
in the more sustained, longer-term responses to threats perceived as more
unpredictable44. While the amygdala response lessens when the immediate threat is
absent, the BNST continues sustained activation and demonstrates the hypervigilant
state observed in some anxiety disorders45. The BNST is centrally located within the
anxiety neurocircuitry, with connections to other limbic and brainstem regions such as
the amygdala, anterior insula, and hippocampus44.
Testosterone and Anxiety
Testosterone has been shown to be anxiolytic across many studies, particularly
through action of its metabolites, dihydrotestosterone (DHT) and 3-alphaandrostanediol, on androgen receptors (AR)6,7,46. Androgens can be converted into
estrogens by aromatase enzymes and act on estrogen receptors, that are also
distributed throughout the CNS47. Testosterone has been demonstrated to act within the
cell through several different pathways. First, classical testosterone signaling occurs
within the cell through a slower, genomic pathway where testosterone binds the nuclear
associated AR. Upon AR binding, testosterone then enters the cell, binds DNA, and
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activates gene transcription . Another mechanism in which testosterone acts is through
48

a non-classical signaling pathway, where testosterone undergoes a faster, pulsative
release. This non-classical, more rapid response to testosterone occurs has been
demonstrated, for example, in courtship and reproductive behaviors48. However, in
terms of anxiety, a faster, pulsative release of testosterone is advantageous, as this
action results in a reduction of anxiety-like behaviors in a shorter period of time. The
mechanism of choice is dependent on which brain region testosterone is acting in, or
whether testosterone will be converted into estrogen by aromatase to act on estrogen
receptors within that region. Reward pathways, including the nucleus accumbens and
the preoptic area in the brain, and pathways that demonstrate anxiolytic effects are
mediated by similar mechanisms involving testosterone48. Interestingly, after
gonadectomy, dopamine release was impaired in the mesolimbic system but was
recovered following DHT supplementation6. Likewise, testosterone administration
enhanced dopamine release in the neostriatum and nucleus accumbens49. Sex steroids
appear to have some level of hormonal control of dopamine release within
dopaminergic pathways in the brain.
Since testosterone is known to be anxiolytic, depressed levels of testosterone
can result in increased anxiety-like behaviors. Individuals with depressed endogenous
testosterone, such as those experiencing the deleterious effects of hypogonadism, have
shown worsened anxiety-like symptoms. Hypogonadism and anxiety have been further
associated in individuals experiencing sexual dysfunction. Anxiety and sexual
dysfunction are positively associated following TBI in men, demonstrated by decreased
intercourse frequency, decreased arousal, and increased erectile dysfunction50. A 70%
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increased risk of sexual dysfunction is also observed among female patients after TBI
as well51. Low-dose testosterone administration was found to reduce anxiety-like
behaviors and improve depression ratings in both males and females6. Efficacy of
testosterone administration on anxiety is dependent on length of androgen deficiency
and age of the patient52. The mechanism by which testosterone supplementation
reduces anxiety in those who are hypogonadal, either acutely or chronically, remains
unknown.
Oxidative Stress and Neurodegeneration
Mitochondrial dysfunction has been implicated in neuronal degeneration and
subsequent neuronal cell death in the brain. Mitochondria are key regulators of cell
death, as they control rates of reactive oxygen species generation and detoxification,
control release of proapoptotic factors, and regulate the respiration rate of the cell53,54.
Mitochondrial dysfunction has been identified after mTBI through a reduction in N-acetyl
aspartate, ATP, and acetyl-CoA levels55. These molecules are markers of proper
mitochondrial function, so a reduction in any or all of these markers after rmTBI would
demonstrate mitochondrial dysfunction. Similarly, a reduction in an important marker for
proper mitochondrial function, cytochrome c oxidase subunit 4 isoform 1 (COX4i1)
within complex IV of the electron transport chain, has been shown within the brains of
animals with neurodegenerative diseases, such as Alzheimer’s disease56,57. In
particular, COX4i1 expression was reduced in Alzheimer’s disease transgenic mice,
which demonstrated mitochondrial dysfunction through impaired mitochondrial
metabolism56. As the rate-limiting enzyme and terminal node in the mitochondrial
electron transport chain, dysfunction of the COX complex is associated with oxidative
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stress in mitochondria . Changes in COX4i1 subunit expression could impact how a
cell is producing ATP and its overall function. Genetic variants of COX4i1 have been
associated with severe epilepsy, intellectual disability, and developmental regressions57.
Together, these findings suggest that COX4i1 expression, as a marker of proper
mitochondrial function, could be reduced within the mitochondria of neurons within the
regions affected by secondary effects of TBI, including the amygdala. This reduction is
associated with mitochondrial oxidative stress. Neurodegenerative diseases, such as
Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis, further point to
associations between psychiatric disorders and the involvement of mitochondrial
dysfunction.
Oxidative Stress and the Amygdala
Oxidative stress has been associated in anxiety, depression, and other mood
disorders through pro-inflammatory processes that result in an increase in reactive
oxygen species and reactive nitrogen species59. Increased production of reactive
oxygen species and reactive nitrogen species can result in stress at a cellular level,
which can lead to cell dysfunction and even cell death. On a behavioral level, these
processes can further exacerbate the detrimental behavioral effects of disorders
associated with mental health and wellness. The brain is sensitive and vulnerable to
oxidative stress due to the amount of oxygen the brain requires to function when
compared to many other organs in the body60. The amygdala is particularly susceptible
to the effects of oxidative stress and imbalances of reactive oxygen species and
antioxidants, as dysfunction in the amygdala due to increased oxidative stress is
associated with an increased chance of developing the mental health disorders
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61,62

previously mentioned

. One study demonstrated susceptibility of the amygdala to

oxidative stress through induction of xanthine and xanthine oxidase treatment followed
by measurement of two different indices of oxidative stress, 8-isoprostane and
malondialdehyde, present within the amygdala brain tissue63. 8-isoprostane was
significantly increased in urine and serum, and malondialdehyde was specifically
increased in the amygdala and the hippocampus, which demonstrated the effect of
oxidative stress that can occur within the amygdala63. Alternatively, others have shown
that oxidative stress within the amygdala can be decreased, or even prevented, in part,
due to moderate physical exercise, which resulted in decreased anxiety-like
behaviors64,65.

CHAPTER THREE
HYPOTHESIS AND SPECIFIC AIMS
Overall Hypothesis
Androgens play a neurotherapeutic role after rmTBI through a reduction in
anxiety-like behaviors and their therapeutic effects are associated with markers of
improved mitochondrial function in dopaminergic neurons in the medial amygdaloid
nucleus.
Specific Aims
Specific Aim 1: To determine the effect hypogonadal status has on anxiety-like
behaviors after rmTBI and to determine whether there is an optimal therapeutic time
window for hormone replacement.
Specific Aim 1a.) To determine whether persistently reduced levels of gonadal
steroids result in prolonged anxiety-like behaviors after rmTBI and whether testosterone
replacement started at a timepoint associated with persistent anxiety reduces anxietylike behaviors.
Specific Aim 1b.) To determine whether reduced levels of gonadal steroids
result in early anxiety-like behaviors following rmTBI and whether testosterone
replacement started at an early timepoint, either immediately or 7 days after rmTBIs,
reduces anxiety-like behaviors.
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Specific Aim 2: To determine whether gonadal steroid status affects a marker of
mitochondrial function in dopaminergic neurons in the medial amygdaloid nucleus after
rmTBI.
Specific Aim 2a.) To determine whether rmTBI alters a marker of mitochondrial
function in dopaminergic neurons in the medial amygdaloid nucleus.
Specific Aim 2b.) To determine if testosterone replacement, either immediately
or 7 days after rmTBIs, increases a marker of mitochondrial function in dopaminergic
neurons in the medial amygdaloid nucleus.

CHAPTER FOUR
RESEARCH DESIGN AND METHODS
Specific Aim 1
To determine the effect changes in gonadal steroid status have on anxiety-like
behaviors after rmTBI and to determine whether there is an optimal therapeutic time
window for hormone replacement.
Experimental Question #1
Will rmTBI lead to anxiety-like behaviors that are not further exacerbated by
castration?
Rationale
Virtually all male patients who have been tested for testosterone levels show
suppressed levels of the hormone immediately after a mTBI. While many recover
gonadal status, a subset of individuals remain chronically hypogonadal. Since
testosterone is known to be anxiolytic, increased anxiety-like behaviors would be
expected in rats that have suppressed testosterone levels due to sustaining rmTBIs. In
addition, this reduction in testosterone can exacerbate anxiety-like behavior that
persists and/or worsens over time. Prolonged anxiety, therefore, could be linked to
gonadal status following rmTBI and must be investigated in order to better understand
how it originates and progresses. Even a single mTBI can lead to anxiety-like
symptoms, so sustaining multiple mTBIs further increases the risk of developing
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anxiety-like symptoms that become persistent and long lasting. A goal of this thesis is to
identify the effect impaired gonadal status and testosterone have on anxiety-like
behaviors following rmTBI. The following experiment will allow for observation of
possible exacerbated anxiety-like behaviors and help identify the effect that
testosterone has on anxiety-like behaviors following rmTBI.
Methods
Animals
8-week old, male Long-Evans Hooded rats were utilized for all experiments. After
arrival to the Edward Hines Jr. VA Veterinary Medical Unit, rats were acclimated to new
housing for three days prior to any handling. Rats were group-housed in controlled
temperature and humidity room with a 12-hour light-dark cycle. Lights were turned on at
6am and turned off at 6pm. Rats were fed standard chow and provided water ad libitum.
All experimental animal procedures were approved by the Edward Hines Jr. VA
Institutional Animal Care and Use Committee (IACUC approval number: 1593048-3).
Animals were randomly assigned into experimental groups as follows: Sham-intact,
Sham-castrate, rmTBI-intact, and rmTBI-castrate, as demonstrated in Figure 1.
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Male Long-Evans
Hooded Rats

Sham

Sham intact

TBI

Sham castrate

TBI intact

TBI castrate

Figure 1. Diagram of Experimental Groups – Aim 1, Experimental Question 1. Four
groups will be utilized in this experiment. Groups include Sham-intact, Sham-castrate,
Sham-castrate, rmTBI-intact, and rmTBI-castrate.
The experimental timeline used to address the first experimental question is
presented in Figure 2. On the first day of the experiment, the first rmTBI was given and
animals were either castrated to represent hypogonadism assumed after the first mTBI
or had undergone sham castration. After the first rmTBI, four subsequent mTBIs
occurred, each spaced 48 hours apart. The 48-hour window between each of the mTBIs
was chosen based on previous similar models of rmTBI. The largest amount of cellular
disruption after a mTBI occurs beings to subside within the first 48-hour period.
Therefore, an adequate period of 48-hours was used to allow cellular disruption to
subside before another mTBI was delivered. The open field behavioral test was
conducted on PTD 28 to observe anxiety-like behaviors.
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48 hrs
TBI #1
CAS

TBI #3

TBI #2

TBI #4

TBI #5

OF

PTD 0

PTD 28

TBI – Traumatic Brain Injury
CAS – Castration
OF– Open Field Test
PTD – Post-final TBI day

Figure 2. Timeline for Experiments – Aim 1, Experimental Question 1. The timeline
for experiments proposed in Aim 1, Experimental question 1 is illustrated in this figure.

rmTBI Model using CCI
A closed-headed CCI electromagnetic device was used to provide mTBI to male
Long-Evans Hooded rats. Figure 3A shows the closed-headed CCI device. The animal
was anesthetized with isoflurane and was placed on a foam pad during impact to
ensure there was free range of head movement, which allowed not only for the coup
injury from impact, but the contrecoup of the brain on the side of the skull opposite from
impact due to acceleration and deceleration forces. The CCI was positioned over the
animal’s skull approximately 20 degrees from vertical and halfway between the eye and
the tip of the ear. This impactor tip was located over the right sensorimotor cortex region
of the brain, shown in Figure 3B. These landmarks have been determined by a previous
group and are used to produce a TBI consistently placed, as verified by measurements
compared to bregma103. This region was chosen so that motor function would not be
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impaired following rmTBI. Just prior to injury, the nose cone providing isoflurane was
removed to allow for impact and free range of head motion. After the nose cone was
removed, the impactor, with a 5 mm steel impactor tip, traveled at approximately 6.5
m/s at a depth of 10mm with a dwell time of 300ms. Immediately after impact, the skull
was checked to ensure there were no signs of fracture after rmTBI. Half of the animals
either received a mTBI by the CCI device (rmTBI group) or a sham impact in which they
receive isoflurane and were placed on the foam pad under impactor without injury
(sham group). The first mTBI was then followed by four consecutive mTBIs, each
spaced 48 hours apart. The fifth and final mTBI was defined as post-injury day (PTD) 0.

A

B

Figure 3. Experimental Repeat Mild TBI Rat Model. A) CCI device setup including
stereotaxic frame with electromagnetically-driven piston, 5 cm thick foam pad, plexiglass
shield along left side of foam, CCI control box, electromagnetic actuator, and nose cone
providing isoflurane. B) Location and orientation of impactor tip on rat skull over right
hemisphere sensorimotor cortex (Pictures from Segismundo, 2019).

23
Castration
Animals were further divided into castration or sham castration (intact) groups.
Animals were placed under 4% isoflurane and maintained at 2% isoflurane for duration
of mTBI induction and surgery. Animals under anesthesia received rmTBI or sham
injury and were immediately castrated or received sham castration surgery. Castrated
groups received an approximate 1-cm incision made in the midline of the scrotum using
surgical scissors. The left cremaster muscle and tunica vaginalis were then opened to
expose the testis and spermatic cord. The testis was then pulled out of the surrounding
sac and a thin silk suture ligated the spermatic cord. A distal cut was then made to
remove the testis and associated spermatic cord. The remaining spermatic cord was
placed back into the surrounding sac and then back into the scrotum. This procedure
was then repeated on the right testis using the same midline scrotal incision. Following
the removal of the other testis, the incision was closed using an 8-mm staple. The other
half of the animals received an incision along the midline of the scrotum but the testes
were not removed, representing the sham group controlling for the incision itself known
as the intact group. The intact group then received the staple to close the incision.
Behavioral Test for Anxiety-like Behavior
Open field behavioral test. Rats were placed in the open field arena for 10 min
and their movement was tracked while they freely explored the arena. The floor of the
arena was marked with blue grid lines that separates the arena into 25 smaller squares,
as well as a red square in the center of the arena comprised of 9 squares that comprise
the “center square”. The 16 outer squares that touch the four walls comprise the
periphery of the arena. An image of the open field apparatus is presented in Figure 4.
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Rats were placed within the center of the red center square at the beginning of the 10
min session. After test, the rats were removed from the open field arena and placed
back into their respective cage.
Observational variables included:
a)

Latency in time to leave center square: time in seconds from placement in the

center red square to time when all four limbs are outside of the red center square.
b)

Total number of red lines crossed

c)

Total time spent in red center square in seconds

d)

Time spent freezing, which excluded small movements of the head or movement

required for breathing, in seconds
e)

Exploring: time spent in the arena doing anything other than grooming or freezing

in seconds
f)

The number of wall explorations: number of rears or “high-leaning” behavior,

when the animal is actively leaning on the walls or looking above the wall and outside of
the arena with two front limbs on the wall.
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Figure 4. Open Field Apparatus. Image of the open field apparatus utilized in all
behavioral experiments. Single frame image taken using video recording device.
Power Analysis
Power analysis was conducted using the statistical program, G*Power 3.1. For
Specific Aim 1, experimental question 1, an a priori ANOVA: between factors, F test
was chosen in order to determine sufficient sample size required for an effect to be
detected within the behavioral tests. Four groups were utilized for this behavioral test,
which include: sham-intact, sham-castrate, rmTBI-intact, and rmTBI-castrate. Therefore,
the two main factors tested were rmTBI and castration. An effect size of 0.8 was chosen
as the smallest effect size to be considered meaningful for the behavioral experiments.
Previous rodent mTBI models that utilized behavioral tests like the open field arena

26
demonstrated a meaningful difference when there was a ± 20% change in anxiety-like
behaviors66,67. This change in anxiety-like behaviors reflects a 0.8 effect size, and a
meaningfully significant change in the anxiety-like behaviors in this study comparable to
the previous studies. The α level is p=0.05, the probability of β error is 0.05, and the
corresponding power is 0.95 (1-0.05). Using these parameters in G*Power 3.1, the noncentrality parameter value produced was 14.72 and the critical F was 4.38. The total
sample size required was 23 for the four groups, which is 5.75, rounded up to 6 animals
per group, which results in an actual power of 0.953. This value represents a 95.3%
chance of seeing a difference at the given effect size of 0.8. It must be noted that the
total sample size utilized in this first experiment was larger than the sample size
acquired through the power analysis. The total sample size for the four groups was 47,
or about 12 per group. The reason more samples were utilized was because of further
manipulations made in a later experiment. Animals from the four groups were to be
further split into groups that did or did not receive treatment. Therefore, the sample size
used for this first experiment was approximately double the calculated sample size. A
large enough number was needed at the end of the study, which required more animals
to be utilized since all animals would be included in the open field behavioral test at
PTD 28.
Statistical Analysis
Statistically significant changes in the behavioral observational variables in the
open field test at PTD 28 were analyzed using a two-way ANOVA statistical test. The
main effects measured were rmTBI and castration. A p-value of <0.05 was used to
determine statistical significance.

27
Experimental Question #2: Do anxiety-like behaviors in rats persist after rmTBI,
castration, or combination of the two?
Rationale
Anxiety-like behaviors that persist at PTD 28 as a result of rmTBI and/or
castration could continue to worsen due to persistently suppressed serum testosterone
levels in animals with hypogonadal status. Many studies report increased anxiety-like
behavior up to one month after mTBI66,67, but some also report that anxiety-like
behaviors begin to fade after one month68. For this reason, the next step was to
determine if increased anxiety-like behaviors would persist, or become exacerbated, at
PTD 42 in animals that endured rmTBI, castration, or both. Alternatively, this experiment
would also demonstrate whether anxiety-like behaviors waned over time without
treatment or intervention. The experimental timeline utilized for this experimental
question is shown in Figure 5.
48 hrs

BD
TBI #1
CAS

TBI #3

TBI #2

TBI #4

TBI #5

OF

PTD 0

PTD 42

TBI – Traumatic Brain Injury
CAS – Castration
OF– Open Field Test
PTD – Post-final TBI day

Figure 5. Timeline for Experiment – Aim 1, Experimental Question 2. The timeline for
experiment proposed in Aim 1, experimental question 2 are illustrated in this figure.
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Methods
Statistical Analysis
Statistically significant changes in the behavioral observational variables in the
open field test at PTD 42 were analyzed by a two-way ANOVA statistical test. The main
effects measured were rmTBI and castration. A p-value of <0.05 was utilized to
determine statistical significance.
Experiment Question #3: Will testosterone supplementation reduce persistent anxietylike behaviors in rats?
Rationale
Since testosterone has been shown to be anxiolytic, and testosterone
suppression has been demonstrated in individuals after rmTBI, it was determined
whether replacement of testosterone could reduce anxiety-like behaviors.
Supplementation with testosterone brought circulating levels to physiological levels. If
testosterone loss that follows rmTBI contributes to increased anxiety-like behaviors,
then it would be expected that animals supplemented with testosterone would show less
anxiety-like behaviors in the open field behavioral test. Individuals that experience
persistent anxiety after rmTBI could greatly benefit from the neurotherapeutic and
anxiolytic effects of testosterone supplementation if provided with the most effective
dosage and at the most effective timepoint after rmTBI. Testosterone supplementation
has the potential to substantially impact recovery following rmTBI and requires further
investigation so that it can become a more therapeutic intervention following TBI. The
experimental timeline for the second experimental question is presented in Figure 6.
This figure depicts the mTBI given and castration surgery that occurred on the first day,
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followed by four subsequent mTBIs spaced 48 hours apart. The open field behavioral
test was then conducted at PTD 28. Testosterone supplementation was then provided
at PTD 35 and the open field behavioral test was conducted once again at PTD 42, one
week following supplementation. A change score was calculated for the frequency or
duration of anxiety-like behaviors from PTD 28 to PTD 42. These scores were
calculated by taking the value from each individual animal at PTD 42 for a particular
observational variable and subtracting the value from that same animal at PTD 28.
48 hrs
TBI #1
CAS

TBI #3

TBI #2

TBI #4

TBI #5

OF #1

TS

OF #2

PTD 0

PTD 28

PTD 35

PTD 42

TBI – Traumatic Brain Injury
CAS – Castration
OF– Open Field Test
PTD – Post-final TBI day
TS – Testosterone Supplementation

Figure 6. Timeline for Experiment – Aim 1, Experimental Question 3. The timeline for
experiment proposed in Aim 1, experimental question 2 are illustrated in this figure.

Methods
Testosterone Supplementation
Testosterone was administered to rats through silastic implants of crystalline
testosterone delivered subcutaneously in the dorsal nape of the neck. Testosterone was
packed into a 1.5 cm long silastic tube with a diameter of 1.57 mm and was sealed with
wooden stoppers and silicone-based medical adhesive at each end. The testosterone
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packed into the capsule was 1.0 cm in length, with each stopper approximately 0.25 cm
in length. Sealing both ends of the capsule with a silicone-based medical adhesive
prevents levels of testosterone rising to supraphysiologic levels in the serum.
Testosterone capsules were placed into phosphate buffered saline overnight prior to
administration in order to prime the testosterone within the capsule before placement
into the subcutaneous space in the nape of the neck. Testosterone capsules were
placed 35 days after the final rmTBI. The subcutaneous implantation of the testosterone
capsule produces an average serum testosterone level of 4.49 ± 1.40 ng/ml in rats69.
Power Analysis
For Specific Aim 1, experimental questions 3, an a priori ANOVA: between
factors, F test was chosen in order to determine sufficient sample size in behavioral
tests with 4 groups, including rmTBI-intact + testosterone supplementation, rmTBI-intact
without testosterone supplementation, rmTBI-castrate + testosterone supplementation,
and rmTBI-castrate without testosterone supplementation. An a priori decision was
made to only utilize the rmTBI groups for this analysis, since they were the groups of
greatest interest to study the effects of testosterone supplementation. An effect size of
0.8 was chosen, as in the previous experiments, to obtain a meaningful difference in
changes in anxiety-like behavior. The α level is p=0.05, the probability of β error is 0.05,
and the corresponding power is 0.95. Using these parameters in G*Power 3.1, the noncentrality parameter value produced was 14.72 and the critical F was 4.38. The total
sample size required was 23 for the 4 groups, which is 5.75 and rounds up to 6 animals
per group, which results in an actual power of 0.953. This value represents a 95.3%
chance of seeing a difference at the given effect size of 0.8.
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Statistical Analysis
Statistical significance in the change score of anxiety-like behavior variables in
the open field test between PTD 28 and PTD 42 was analyzed using a two-way ANOVA
statistical test. The main factors were castration and testosterone treatment. A p-value
of <0.05 was used to determine statistical significance.
Experiment Question #4: Will testosterone supplementation at a more acute timepoint,
either immediately or 7 days after the final rmTBI, reduce anxiety-like behaviors in rats
at PTD 14?
Rationale
After observing increased and prolonged anxiety-like behavior in animals
following rmTBI, the next step was to identify whether this increased anxiety-like
behavior was normalized, or even eliminated, at an earlier timepoint through
testosterone supplementation. Testosterone supplementation either immediately or 7
days after the final rmTBI was used to characterize effects of testosterone on anxietylike behaviors. The experimental groups were presented in Figure 7. This figure shows
the sham-intact, sham-castrate, rmTBI-intact, and rmTBI-castrate, further separated into
testosterone treatment groups. The sham-castrate group was separated into shamcastrate without testosterone or with 7-day testosterone. The immediate testosterone
treatment group for sham-castrate was not included since testosterone levels would be
approximately the same as the sham-intact once testosterone was removed through
castration and immediately replaced. In addition, rmTBI-castrate was split into rmTBIcastrate without testosterone, with immediate testosterone, or with 7-day testosterone.
Since a critical window for testosterone supplementation has not yet been determined,
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this experiment was designed to explore if testosterone is neurotherapeutic when
reintroduced at the earlier timepoints described above. The experimental timeline was
presented in Figure 8. This timeline follows the previously used timeline in Figure 6 with
the same TBI induction and castration setup. However, the immediate testosterone
supplementation timepoint has been added on the first day of rmTBI induction and a 7day testosterone supplementation timepoint on PTD 7. The open field behavioral test
was conducted on PTD 14 and animals were sacrificed on PTD 15. This experiment
was designed to help determine if supplementation with testosterone at an earlier time
point (immediately or at PTD 7) would reduce anxiety-like behaviors at PTD 14 in this
experimental rmTBI rat model. There could be a critical window of time in which
testosterone is needed following a TBI, potentially at a time when hypogonadal
individuals will not have testosterone. If testosterone can be given back to the individual
at an earlier timepoint following injury, before development of anxiety and other
deleterious symptoms, it could have significant effect on the individual and not only
improve symptoms but could prevent new symptoms from developing.
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Male Long-Evans
Hooded Rats

Sham

TBI

Sham intact

Sham castrate

TBI intact

No
testosterone

TBI castrate

Immediate
testosterone

7 days
testosterone

No
testosterone
7 days
testosterone

Figure 7. Diagram of Experimental Groups – Aim 1, Experimental Question 4. There
will be 7 groups utilized in this experiment. Groups include Sham-intact, Sham-castrate +
T at 7 days, Sham-castrate + No T, TBI-intact, TBI-castrate + immediate T, TBI-castrate
+ T at 7 days, and TBI-castrate + no T.
BD
TBI #1
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T-IM
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TBI #3

TBI #2

TBI #4

TBI #5

T-7

PTD 0

PTD 7
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TC
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TBI – Traumatic Brain Injury
CAS – Castration
T-IM – Testosterone supplementation immediately
T-7 - Testosterone supp. PTD 7
OF – Open Field Test
PTD – Post-final TBI day
TC – Tissue Collection

Figure 8. Timeline for Experiments – Aim 1, Experimental Question 4. The timeline
for experiments proposed in Aim 1, Experimental Question 4 are illustrated in this figure.
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Statistical Analysis
Statistically significant changes in the behavioral observational variables in the
open field test at PTD 14 were determined using a multiple linear regression statistical
model (Linear regression factors = castration, rmTBI, immediate treatment, and 7-day
treatment). A p-value of <0.05 was used to determine statistical significance.
Specific Aim 2
To determine whether gonadal steroid status affects a marker of mitochondrial
function in dopaminergic neurons in the medial amygdaloid nucleus after rmTBI.
Experimental Question #5: How does rmTBI affect a marker of mitochondrial function
in dopaminergic neurons in the medial amygdaloid nucleus?
Rationale
The rate-limiting enzyme in catecholamine synthesis, tyrosine hydroxylase (TH),
has been shown to be highly expressed on neurons in key areas related to anxiety.
Specifically, the posterior medial amygdaloid nucleus, an area associated with social
and sexual behaviors, contains high expression of both TH and androgen receptors70.
Since TH is the rate-limiting enzyme in both dopamine and norepinephrine biosynthesis
pathways, it is critical to explore presence of dopamine beta hydroxylase (DBH), as the
enzyme that converts dopamine into norepinephrine, used as a proxy to distinguish cell
type within the medial amygdaloid nucleus.
Dopaminergic neurons in the medial amygdaloid nucleus could experience a
reduction in the level of mitochondrial function as a result of sustained rmTBIs. COX4i1
is the cytochrome c oxygenase subunit associated with complex IV of the mitochondrial
respiratory chain. Reduced COX4i1 expression, then, is associated with impaired
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mitochondrial function . Mitochondrial dysfunction can lead to increased oxidative load
71

and cellular stress in dopaminergic neurons. Oxidative stress, if left unchecked, can
then lead to dopaminergic neuronal cell death. The level of mitochondrial dysfunction
after rmTBI could be a key component in the development and exacerbation of anxiety.
In order to experimentally test for mitochondrial dysfunction in dopaminergic
neurons in the medial amygdaloid nucleus, COX4i1, DBH, and TH mRNA expression
markers were identified within that region. Both dopaminergic and noradrenergic
neurons require the catecholamine rate-limiting enzyme, TH, in order to synthesize
neurotransmitter, but DBH further converts dopamine into norepinephrine in
noradrenergic neurons. Therefore, TH-positive, DBH-negative neurons were identified
through fluorescent in situ hybridization in order to visualize and quantify changes in
COX4i1 expression levels within dopaminergic neurons in the medial amygdaloid
nucleus.
Methods
In Situ Hybridization – Fluorescent Multiplex Assay
Animals were sacrificed and brains were quickly extracted and placed into a
beaker of isopentane on dry ice for rapid freezing. Frozen brain tissue was then stored
at -80°C until use. Frozen brain tissue was blocked to obtain the medial amygdaloid
nucleus. Cuts of the frozen brain tissue were made to obtain a tissue block that
contained the medial amygdaloid nucleus, but also regions of the hippocampus and
other subregions of the amygdala. The location of each cut was determined by first
identifying nearby anatomical landmarks and by consulting the Paxinos and Watson Rat
Brain Atlas, 6th edition72. The frozen brain tissue blocks were sectioned into 25µm-thick
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tissue slices at -20°C using a cryostat (Leica CM3050 S Cryostat, Leica Biosystems,
Buffalo Grove, IL 60089) and were mounted onto 1mm thick slides coated with 3Aminopropyltriethoxysilane for adhesion (Electron Microscopy Sciences, Cat. No.
63734-01). Each slide contained two sections of brain tissue. Slides to be utilized for in
situ hybridization were selected through cresyl violet staining and through consulting the
Paxinos and Watson Rat Brain Atlas, 6th edition in order to select slides demonstrating
the same spatial proximity to key anatomical landmarks72. The location and spatial
orientation of the optic nerve, internal capsule, and lateral ventricle were each used to
indicate a consistent position within the medial amygdaloid nucleus between each brain
for in situ experiments.
In situ hybridization was conducted using an RNAscope Fluorescent Multiplex
Assay Kit (acdbio, Cat. No. 320850). COX4i1, DBH, and TH mRNA expression levels
were measured with RNAscope target probes in order to mark differences in mRNA
expression between groups with fluorescent tags. These tags were used to determine
localization of each mRNA within the medial amygdaloid nucleus. Slides were removed
from -80°C and placed onto dry ice. Slides were next submerged and fixed with 4%
paraformaldehyde at 4°C for 15 minutes. After tissue fixation, tissue sections underwent
dehydration, which included 5 minutes in 50% ethanol, 5 minutes in 70% ethanol, 5
minutes in 100% ethanol, and another 5 minutes in fresh 100% ethanol, all at room
temperature. After this dehydration step, slides were removed from ethanol and allowed
to air dry for 5 minutes prior to application of hydrophobic barrier with ImmEdge
hydrophobic barrier pen around each section on the slide. Next, Protease IV reagent
was applied to dried slides and incubated at room temperature for 30 minutes. Protease
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IV was then removed and slides were washed in 1X PBS, followed by another wash in
fresh 1X PBS. Target probes were supplied in two different dilutions. The first target
probe, COX4i1 (acdbio, Cat. No. 425921), was supplied in a diluted, 1X form. The two
other target probes, DBH (acdbio, Cat. No. 316421–C2) and TH (acdbio, Cat. No.
314651-C3), were supplied in a 50X concentration. Therefore, the target probe mixture
required a 50:1:1 dilution ratio for COX4i1, DBH, and TH, respectively. COX4i1, DBH,
and TH target probes were each designed to be exposed to a different fluorescent tag,
selected to optimize detection and quantification. The target probe mixture was applied
in sufficient quantity to completely cover each brain section, at approximately 50 µL.
Slides were incubated at 40°C for 2 hours to hybridize to tissue. Following probe
incubation, probes were removed and slides were washed twice with 1X wash buffer.
The first amplifier, Amp 1, was applied and incubated again at 40°C for 30 minutes to
hybridize. After first amplifier incubation, Amp 1 was removed and slides were washed
twice with 1X wash buffer prior to Amp 2 application. Slides were incubated at 40°C for
15 minutes. Next, Amp 2 was removed, slides were washed twice with 1X wash buffer,
Amp 3 was applied, and then another 30 minutes incubation at 40°C followed to
hybridize. Lastly, Amp 3 was removed, slides were washed twice with 1X wash buffer,
and Amp Alt B (selected based on preferred coloration for each probe to optimize
visualization and quantification) was applied and incubated at 40°C for a final 15
minutes. Following Amp Alt B incubation, slides were washed twice more with 1X wash
buffer and wash buffer remained on slides until mounting media was applied. Next,
wash buffer was removed and DAPI was added to each section and incubated at room
temperature for 30 seconds. Following incubation, DAPI was removed and slides were
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immediately coverslipped using fluorescent mounting media and kept in the dark at 4°C
to preserve fluorescent label for further visualization and quantification. Slides were
visualized through widefield fluorescent microscopy (Olympus IX-81, motorized inverted
system microscope, Olympus Life Science).
In Situ Hybridization – Quantification
COX4i1, DBH, and TH-label in the medial amygdaloid nucleus was observed
using widefield fluorescence microscopy. The Olympus CellSens program was utilized
to make and process images. A multi-image array with z-stacks of the medial
amygdaloid nucleus was taken of the three combined channels for each tissue section
at 20X magnification. Twenty-one Z-slices were taken in each channel, each with a 0.5
micron step size. Images with 21 Z-slices were processed using extended focus image
processing in order to generate a single quantifiable image containing the brightest
pixels from each Z-slice. ROIs could then be drawn using the extended focus processed
images, shown in Figure 9. This image shows an ROI drawn as a red line around a
TH+ cell, represented through clusters of red puncta, and DBH- cell, demonstrated by a
lack of green puncta clusters, using the freeline drawing tool. TH+, DBH- cells were
deemed positive based on pre-selected criteria, including number and shape of puncta,
signal strength of label, and colocalization pattern within each cell body.
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Figure 9. Example of ROI Drawn Around +TH Cell Using CellSens Dimension
Program. This 20X magnified image depicts the medial amygdaloid nucleus from the
CellSens Dimension program demonstrating a TH+ cell with an ROI drawn around the
cell body with the red line. Red puncta represent TH, Blue-DAPI, White-COX4i1
The criteria utilized to select positive cells also took potential channel overlap
resulting in cloudy, unclear puncta shape into account, as well as signs of general
autofluorescence. Only clear, round, and bright puncta that did not demonstrate overlap
with another channel were included in the criterion for number of puncta to be
considered a positive cell as depicted in Figure 10. The red channel, depicted in Figure
10A, and the white channel, depicted in Figure 10B, were separated in order to
determine any overlap between channels or to detect autofluorescence. The overlapped
channel, presented in Figure 10C, demonstrates several areas where white and red
puncta overlap. These areas of overlap are not true signal as they are not clear or bright
as puncta visualized with this technique should be. The amount of COX4i1 expression
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was then quantified within TH+, DBH- ROIs through an automated process on the
software. This was done by setting a threshold for the COX4i1 channel, segmenting the
puncta, and counting the number of puncta present within each of the ROIs.

B

A

C

Figure 10. Example of Channel Fluorescence Overlap and Autofluorescence in
Process of Identifying TH+ Cells. This 20X magnified image demonstrates an example
of fluorescent signal overlap between channels which results in unclear, cloudy puncta
shape that is not true fluorescent signal. Examples of overlap are represented in the
combined image by pink color, indicated by white arrows, compared to separated red and
white channel images. The red channel (A) contains red puncta that represent TH, the
white channel (B) contains white puncta that represent COX4i1, and the red and white
channels overlapping (C) contain pink puncta that represent nonspecific label.
Power Analysis
For Specific Aim 2, experimental questions 5 and 6, an a priori ANOVA: between
factors, F test was chosen in order to determine the sufficient sample size for
fluorescent in situ hybridization with five groups, including Sham-intact, rmTBI-intact,
rmTBI-intact + immediate T, rmTBI-castrate + 7 day T, and rmTBI-castrate + empty
capsule. The standard deviation was set to 1 for all five groups. An effect size of 1.5
was chosen. The α level is p=0.05, the probability of β error is 0.05, and the
corresponding power is 0.95. Using these parameters in G*Power 3.1, the non-centrality
parameter value produced was 42.75 and the critical F was 2.54. The total sample size
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required was 23 for the five groups, which is 4.6, rounded up to 5 animals per group,
which results in an actual power of 0.953. This value represents a 95.3% chance of
seeing a difference at the given effect size of 1.5.
Experimental Question #6: Does testosterone supplementation at a more acute
timepoint, either immediately or 7 days following last rmTBI, result in reduced
mitochondrial dysfunction in dopaminergic neurons in the medial amygdaloid nucleus?
Rationale
Gonads are the major source of gonadal steroid production, so performing a
gonadectomy in animal models will reflect suppressed testosterone levels. Removal of
endogenous testosterone resulted in increased anxiety-like behaviors. Some studies
have reported a neurotoxic role of testosterone when presented to the cellular
microenvironment in states of oxidative stress or neuroinflammation73,74. These studies
often utilize in vitro models or present testosterone early to the microenvironment
following injury. For this reason, identifying a critical window of time in which
testosterone could either be deleterious or beneficial if provided at an earlier timepoint
was essential within the experimental rat rmTBI model.
The effect of testosterone given at an earlier timepoint on mitochondrial function
was measured by COX4i1 expression levels in dopaminergic neurons in the medial
amygdaloid nucleus. If the level of mitochondrial dysfunction is too high in dopaminergic
neurons in the medial amygdaloid nucleus, then supplementing earlier with testosterone
might serve as a way to regulate or help restore proper mitochondrial function.
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Methods
Animals
Sham and TBI groups were further divided into categories based on testosterone
supplementation, as diagramed above in Figure 7. An a priori decision was made to
utilize the five most important groups in order to identify key changes in effect of injury,
castration, and/or treatment on the expression of COX4i1 within the medial amygdaloid
nucleus. For the sham groups, these included a sham castrate with empty capsule
group and a sham castrate with testosterone given 7 days following final injury group.
For the TBI groups, these included a TBI castrate with empty capsule group, a TBI
castrate with immediate testosterone group, and a TBI castrate with testosterone given
at 7 days following final injury group.
Statistical Analysis
Significant changes in the amount of COX4i1 expression in PTD 14 brains were
observed using a two-way ANOVA statistical test. The main factors measured were
rmTBI and testosterone treatment. Since data from all previous groups could not be
applied in this statistical analysis to utilize a full effects model, a main-effects-only model
was required for this analysis. A Dunnett post-hoc multiple comparisons analysis was
utilized to determine significant differences between each rmTBI group compared to the
sham group. A p-value of <0.05 was used to determine statistical significance.

CHAPTER FIVE
RESULTS
Specific Aim 1, Experimental Question 1
Will rmTBI lead to anxiety-like behaviors that are not further exacerbated by
castration?
In the first study, it was determined whether rmTBI would cause anxiety to the
same degree as the loss of testosterone itself. The open field behavioral test, a
standard test used to identify anxiety-like behaviors in rodents, was used in this study75.
Animals in the rmTBI group have been hypothesized to demonstrate significantly
increased frequency and duration of anxiety-like behaviors. In addition, castrated
groups should also demonstrate a similar increase in anxiety-like behaviors since
testosterone is absent or suppressed. Summary data are shown in Figures 11 and 12
and demonstrate the results of the open field behavioral test at one month after the final
rmTBI. The number of red lines crossed and the number of wall explorations, also
known as high-leaning or rearing behavior, were assessed in Figure 11A and 11B,
respectively. Anxiety-like behavior is expressed by less rearing along the outer walls of
the apparatus. A reduced number of red lines crossed is also a measure of increased
anxiety-like behavior. These red lines surround the innermost nine squares in the arena
and outline the center of the arena.
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Figure 11. rmTBI Resulted in Decreased Number of Wall Explorations. (A) Number
of wall explorations and (B) the number of red lines crossed in male Sham and TBI intact
or castrated rats 28 days after rmTBI. The two-way ANOVA did not demonstrate a
statistically significant interaction between rmTBI and castration (F(1,90) = 3.24, p=0.075)
on number of wall explorations. The test did demonstrate a significant main effect of
rmTBI (p=0.005) on the number of wall explorations observed in the open field test 28
days after the last rmTBI. The two-way ANOVA for number of red lines crossed did not
demonstrate a statistically significant interaction between rmTBI and castration (F(1,91)
= 1.682, p=0.20). The test did not demonstrate significant main effects of rmTBI or
castration on mean number of red lines crossed in the open field arena. However, there
was a trend for the main effect of rmTBI on mean number of red lines crossed (p=0.058).
n=23-24 per experimental group. INT = intact, CAS = castrated
Latency time to leave the center, red-lined square was observed to detect
changes in anxiety-like behavior, represented in Figure 12A. The greater the latency
time correlates to less anxiety-like behavior and vice versa. Time spent along the
periphery and outside of the center of the area was also observed as a marker of
anxiety-like behavior. The overall amount of time spent in the inner, red-lined square
was assessed, where less time spent in the inner square equates to greater anxiety-like
behavior. This is represented in Figure 12B. Time spent freezing during the open field
trial indicates anxiety-like behavior. More time spent immobile within the arena is
associated with greater anxiety-like behavior. The mean time spent freezing in the
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arena was shown in Figure 12C. The amount of time spent moving in the open field was
shown in Figure 12D, where more time spent moving equates to reduced anxiety-like
behavior.
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Figure 12. rmTBI and Castration Resulted in Decreased Latency and Increased
Time Freezing at PTD 28, Castration Resulted in Decreased Time in Inner Square.
Behaviors depicted in these graphs include (A) Latency in time to leave the center square,
(B) Time in the inner square, (C) Time spent freezing in open field, and (D) Time spent
exploring, or moving, in the open field at PTD 28. The two-way ANOVA statistical test
did not demonstrate a statistically significant interaction between rmTBI and castration
(F(1,88) = 1.839, p=0.18) on mean latency time to leave center square. However, the test
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did demonstrate significant main effects of rmTBI (p=0.020) and castration (p=0.030) on
the mean latency time in leaving the center square at PTD 28. The two-way ANOVA
statistical test did not demonstrate a statistically significant interaction between rmTBI and
castration (F(1,88) = 0.019, p=0.89) on time spent in the inner, red-lined square. However,
the test did demonstrate a significant main effect of castration on time spent in the inner
square (p=0.048). The two-way ANOVA statistical test did not demonstrate a statistically
significant interaction between rmTBI and castration (F(1,89) = 0.70, p=0.41) on the time
spent freezing in the open field arena. However, the test did demonstrate statistically
significant main effects of rmTBI (p=0.014) and castration (p=0.011) on the amount of
time spent freezing in the arena. The two-way ANOVA statistical test did not demonstrate
a statistically significant interaction between rmTBI and castration (F(1,90) = 0.92,
p=0.34) on the amount of time spent exploring in the open field arena. Likewise, the test
did not demonstrate statistically significant main effects of rmTBI (p=0.32) or castration
(p=0.37) on amount of time spent exploring in the arena. n=23-24 per experimental group.
Bars represent mean ± SEM.
Specific Aim 1, Experimental Question 2
Do anxiety-like behaviors in rats persist after rmTBI, castration, or combination of
both?
This 5-hit closed-headed CCI rmTBI experimental animal model has been
previously shown to lead to significantly reduced serum testosterone levels in the rmTBI
groups compared to the sham groups for at least one month after rmTBI. The next
experiment was designed to determine whether anxiety-like behaviors in rats persisted
in the open field behavioral test at PTD 42, or if the anxiety-like behaviors would begin
to wane over time. The 4 groups from the previous experiment, which were sham-intact,
sham-castrate, rmTBI-intact, and rmTBI-castrate, were utilized again for this
experiment, but included the PTD 42 timepoint. Similar to the last experiment, none of
the anxiety-like behaviors observed at PTD 42 in Figures 13 and 14 demonstrated a
significant interaction between rmTBI and castration on anxiety-like behavior. However,
there again were multiple significant main effects present at this timepoint.
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Figure 13. rmTBI Resulted in Fewer Red Lines Crossed at PTD 42. Graphs include
behavioral data from open field behavioral test 42 days after final rmTBI. The two-way
ANOVA for number of red lines crossed did not demonstrate a statistically significant
interaction between rmTBI and castration (F(1,43) = 0.0035, p=0.95). The test did
demonstrate a significant main effect of rmTBI on mean number of red lines crossed in
the open field arena (p=0.02). The test did not demonstrate a significant main effect of
castration on mean number of red lines crossed (p=0.11). The two-way ANOVA for
number of wall explorations did not demonstrate a statistically significant interaction
between rmTBI and castration (F(1,43) = 0.032, p=0.86). The test also did not
demonstrate significant main effects of rmTBI (p=0.11) or castration (p=0.55) on number
of wall explorations in the open field arena. n=11-12 per experimental group. Error bars
represent mean ± standard error of the mean (SEM).
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Figure 14. rmTBI Resulted in Decreased Latency Time and Time in Inner Square at
PTD 42. These graphs depict (A) the mean latency to leave center square, (B) time spent
in the inner square, (C) time spent freezing, and (D) time spent exploring the open field
42 days after final rmTBI. The two-way ANOVA test did not demonstrate a statistically
significant interaction between rmTBI and castration (F(1,41) = 1.20, p=0.28) for the mean
latency time to leave the inner square. The test did demonstrate a significant main effect
of rmTBI on latency time to leave the inner square of the open field arena (p=0.02). The
test did not demonstrate a significant main effect of castration on latency time to leave
the inner square (p=0.93). The two-way ANOVA test did not demonstrate a statistically
significant interaction between rmTBI and castration (F(1,43) = 0.002, p=0.97) for the time
spent in the inner square of the open field arena. The test did demonstrate a significant
main effect of rmTBI on time spent in the inner square of the open field arena (p=0.04).
The test did not demonstrate a significant main effect of castration on time spent in the
inner square (p=0.35). The two-way ANOVA test did not demonstrate a statistically
significant interaction between rmTBI and castration (F(1,21) = 0.33, p=0.57) for the mean
time spent freezing in the open field arena. The test did not demonstrate significant main
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effects of rmTBI (p=0.64) or castration (p=0.44) on time spent freezing in the open field
arena. The two-way ANOVA test did not demonstrate a statistically significant interaction
between rmTBI and castration (F(1,21) = 1.16, p=0.29) for the mean time spent exploring
in the open field arena. The test did not demonstrate significant main effects of rmTBI
(p=0.37) or castration (p=0.84) on time spent exploring in the open field arena. Error bars
represent mean ± SEM. n=11-12 per experimental group for 14A and 14B. n=4-7 per
experimental group for 14C and 14D. INT = intact, CAS = castrated.
Specific Aim 1, Experimental Question 3
Will testosterone supplementation reduce persistent anxiety-like behaviors in
rats?
Since anxiety-like behaviors persisted 42 days after the final rmTBI, and were
significantly increased due to rmTBI, testosterone supplementation was given to the
rmTBI groups to reduce persistent anxiety-like behaviors. Since the effect of
testosterone supplementation on sham groups was not as relevant in the next
experiment, only rmTBI groups given testosterone supplementation were analyzed in
this statistical analysis. Also, a repeat measures four-way ANOVA is difficult to interpret
and would not provide as much insight to help and answer the question posed in this
experiment. In order to distinguish if testosterone supplementation could reduce
persistent anxiety-like behaviors, testosterone capsules were implanted in rats at PTD
35 and the open field behavioral test was conducted again one week later, at PTD 42.
The animals in this experiment were tested in the open field arena twice, at PTD 28 and
PTD 42. A change score was calculated to determine the change in frequency or
duration of previously identified anxiety-like behaviors. These scores were calculated by
taking the value from each individual animal at PTD 42 for a particular observational
variable and subtracting the value from that same animal at PTD 28. A positive change
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score means that the animal exhibited a higher frequency or a longer duration of that
event on PTD 42 than at PTD 28. Interestingly, there were no significant interactions or
main effects of rmTBI or testosterone treatment on any of the anxiety-like behaviors
observed from PTD 28 to PTD 42. The testosterone treatment did not result in a
significant decrease in anxiety-like behavior at PTD 42, one week after testosterone
was given systemically. Summary data for change scores for anxiety-like behaviors are
represented in Figures 15 and 16. These anxiety-like behaviors persisted at PTD 42
and did not improve with treatment given at PTD 35.
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Figure 15. No Change in Number of Red Lines or Wall Explorations from PTD 28 to
PTD 42. Graph depicts average change score from PTD 28 to PTD 42, 7 days post
testosterone treatment, for (A) number of red lines crossed and (B) number of wall
explorations. Change score is calculated by taking the value at PTD 42 – value at PTD
28 for each animal in each group, represented as individual points on graph. The twoway ANOVA analysis for change in number of red lines crossed did not demonstrate a
statistically significant interaction between castration and testosterone treatment (F(1,24)
= 0.90, p=0.35). The test did not demonstrate a significant main effect of castration on
mean change in number of red lines crossed in the open field arena (p=0.17). The test
did not demonstrate a significant main effect of testosterone treatment on mean change
in number of red lines crossed (p=0.59). The two-way ANOVA analysis for change in
number of wall explorations did not demonstrate a statistically significant interaction
between castration and testosterone treatment (F(1,24) = 1.28, p=0.27). The test did not
demonstrate a significant main effect of castration on mean change in number of wall
explorations in the open field arena (p=0.16). The test did not demonstrate a significant
main effect of testosterone treatment on mean change in number of wall explorations
(p=0.10). n=7 per experimental group. Error bars represent mean ± SEM.
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Figure 16. No Change in Time Spent in Inner Square, Latency Time, Time Freezing,
or Time Exploring from PTD 28 to PTD 42. Graph depicts average change score from
PTD 28 to PTD 42, 7 days post testosterone treatment, for (A) time in the inner square,
(B) latency time to leave inner square, (C) time spent freezing, and (D) time spent
exploring. Change score is calculated by taking the value at PTD 42 – value at PTD 28
for each animal in each group, represented as individual points on graph. The two-way
ANOVA analysis for change in time spent in inner square did not demonstrate a
statistically significant interaction between castration and testosterone treatment (F(1,22)
= 0.84, p=0.37). The test did not demonstrate a significant main effect of castration on
mean change in time spent in inner square of the open field arena (p=0.53). The test did
not demonstrate a significant main effect of testosterone treatment on mean change in
time spent in inner square (p=0.53). The two-way ANOVA analysis for change in latency
time to leave inner square did not demonstrate a statistically significant interaction
between castration and testosterone treatment (F(1,24) = 0.04, p=0.84). The test did not
demonstrate a significant main effect of castration on mean change in latency time to
leave inner square of the open field arena (p=0.62). The test did not demonstrate a
significant main effect of testosterone treatment on mean change in latency time to leave
inner square (p=0.50). The two-way ANOVA analysis for change in time spent freezing in
open field arena did not demonstrate a statistically significant interaction between
castration and testosterone treatment (F(1,24) = 0.06, p=0.80). The test did not
demonstrate a significant main effect of castration on mean change in time spent freezing
in the open field arena (p=0.58). The test did not demonstrate a significant main effect of
testosterone treatment on mean change in time spent freezing (p=0.51). The two-way
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ANOVA analysis for change in time spent exploring in open field arena did not
demonstrate a statistically significant interaction between castration and testosterone
treatment (F(1,21) = 0.006, p=0.94). The test did not demonstrate a significant main effect
of castration on mean change in time spent exploring in the open field arena (p=0.15).
The test did not demonstrate a significant main effect of testosterone treatment on mean
change in time spent exploring (p=0.84). n= 6-7 per experimental group. Error bars
represent mean ± SEM.
Specific Aim 1, Experimental Question 4
Will supplementing with testosterone at a more acute timepoint, either immediately
or 7 days following the last rmTBI, reduce anxiety-like behaviors in rats?
Throughout the previous experiments, ANOVA statistical tests were utilized to
analyze the behavioral data. However, once the experimental design included the
testosterone supplementation factor, 3-way ANOVA tests were required and could not
be accurately analyzed with this experimental design. This was due to an uneven
number of samples within each group, as well as some groups being absent from this
analysis. For example, the sham-castrate plus immediate testosterone treatment group
was excluded from this analysis since it was deemed unnecessary, as this group would
be no different physiologically than the sham-intact group. Therefore, multiple linear
regression models were used in this experiment and all subsequent experiments in this
thesis to effectively analyze and interpret the behavioral data. The factors included in
this regression included rmTBI, castration, and testosterone supplementation. Figure 17
demonstrates the mean time spent in the inner square during the 10 minute trial in the
open field arena amongst all experimental groups. Anxiety-like behavior was
significantly reduced following immediate testosterone, but not 7-day testosterone, in
the rmTBI-intact group.
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Figure 17. Injured Rats Demonstrated Reduced Time in Inner Square, Reversed by
Immediate Testosterone Treatment. Graph includes rats from each experimental
group at PTD 14, either one week (7-day T) or two weeks (Immediate T) after
testosterone treatment. The multiple linear regression model was used to test if rmTBI,
castration, and testosterone treatment significantly predicted the time spent in the inner
square. The fitted regression model was time spent in the inner square (sec) = 33.51 –
12.36*(rmTBI) + 18.03*(immediate testosterone treatment). The overall regression for
the data was statistically significant (R2=0.1536, F(4,60) = 2.723, p=0.04). It was found
that rmTBI predicted the time spent in the inner square (𝛽= -12.36, p=0.008). It was also
found that immediate testosterone treatment predicted the time spent in the inner
square (𝛽= 18.03, p=0.012). Castration was not a predictor of time spent in the inner
square (p=0.72), nor was 7-day testosterone treatment a predictor of time spent in the
inner square at PTD 14 (p=0.54). p<0.05 = *. n=8-10 per experimental group. Error bars
represent mean ± SEM.
Specific Aim 2, Experimental Question 5
How does rmTBI affect a marker of mitochondrial function in dopaminergic
neurons in the medial amygdaloid nucleus?
The medial amygdaloid nucleus contains TH+ cells that also highly express ARs
in several species of rodents, which include the Syrian hamster70 and the prairie vole76.
Since testosterone is suppressed after rmTBI and the medial amygdaloid nucleus,
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involved in defensive and anxiety-related social behaviors, contains a high level of AR
expression, the effect of androgens within this brain region are important to explore after
rmTBI. This thesis is one of the first academic works to demonstrate the presence of TH+
cells within rat medial amygdaloid nucleus. The data collected and analyzed from the in
situ experiments in this thesis demonstrated clusters of TH mRNA through in situ
hybridization that represent TH+ cells in rat medial amygdaloid nucleus. The animals
utilized in specific aim 2 are those from the early anxiety timepoint behavioral data at PTD
14. Animals tested in the open field arena at PTD 14 were sacrificed at PTD 15 and brains
were quickly extracted. These animals had been tested in the open field only once the
day prior to sacrifice. In order to identify TH+ cells within the medial amygdaloid nucleus,
fluorescence in situ hybridization was utilized to detect TH mRNA expression. TH+ cells
were selected and quantified by drawing regions of interest (ROI) around each TH
positive cell, deemed positive based on pre-selected criteria and depicted by a red line,
using a freehand drawing tool in the CellSens Dimension computer program. Criteria
utilized to determine a TH+ cell included: at least five nuclear-associated puncta, puncta
were circular in shape, puncta were bright, and puncta still met all previous criteria after
eliminating autofluorescence or bleed through between channels. An example of a TH+
cell, depicted by the presence of clusters of red TH puncta within blue-colored cell bodies
stained with DAPI, are presented in Figure 18 in a rmTBI-intact rat.
TH+ cells were identified in both sham and rmTBI animals. However, rmTBI
animals demonstrated clearer, more distinct TH+ signal compared to sham animals.
This was determined through a qualitative assessment as clusters of TH puncta
appeared brighter and more concentrated within the nucleus in the rmTBI group (Figure
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18B) compared to the sham group (Figure 18A). Once TH+ cells were identified, ROIs
were drawn around TH mRNA puncta with red lines using a freehand drawing tool.
These ROIs depicted regions of the nucleus with a high density of TH mRNA puncta,
where the mRNA was likely being transported outside of the nucleus and followed the
previously defined criteria to be a TH+ cell. Representative images for mean number of
ROIs per experimental group is demonstrated in Figure 18. The representative image
for mean number of ROIs in sham animals is presented in Figure 18A. Likewise, the
representative image for mean number of ROIs in rmTBI animals is presented in Figure
18B. TH puncta, regardless of ROI designation, appear more diffusely spread across
the medial amygdaloid nucleus within the sham group, demonstrated in Figure 18A,
compared to more concentrated TH puncta present within ROIs in the medial
amygdaloid nucleus in the rmTBI group, demonstrated in Figure 18B.
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Figure 18. Representative Examples of Number of ROIs Between Sham and rmTBI
Groups. These images provide representative examples of the number of ROIs taken
at 20X magnification in the medial amygdaloid nucleus. Images are presented as
follows: (A) sham and (B) rmTBI. DAPI = blue staining, TH = red puncta. Red circles
indicate TH+ cells.
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Specific Aim 2, Experimental Question 6
Does testosterone supplementation at a more acute timepoint, either immediately
or 7 days following last rmTBI, result in a reduced marker of mitochondrial dysfunction
in dopaminergic neurons in the medial amygdaloid nucleus?
In order to visualize and quantify differences in the amount of COX4i1 mRNA
expression, the ROIs previously drawn around TH+ cells were used to evaluate the
amount of COX4i1 puncta within each ROI. Qualitative differences prior to quantification
between sham, rmTBI without testosterone treatment, rmTBI with immediate
testosterone treatment, and rmTBI with 7-day testosterone treatment are depicted in
Figure 19.
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Figure 19. Representative Examples of COX4i1 mRNA Expression in Sham,
rmTBI, rmTBI + Immediate Testosterone, and rmTBI + 7-day Testosterone. These
images provide representative examples of the number of COX4i1 puncta present
within TH+ ROIs taken at 20X magnification in the medial amygdaloid nucleus. The
sham group, represented in Figure 11A, portrays a 20X magnified image and depicts
the white COX4i1 puncta present within both the entire section and within each ROI
drawn with a red circle. The rmTBI group, represented in Figure 11B, similarly
demonstrates the same magnification and white COX4i1 puncta present in each ROI as
within the sham intact group. Both rmTBI with immediate testosterone (Figure 11C) and
rmTBI with 7-day testosterone (Figure 11D) demonstrate the same medial amygdaloid
nucleus region, but after respective treatment with testosterone. Red circles indicate
TH+ cells. White puncta – COX4i1, Blue – DAPI staining.
Summary data for mean number of TH+ ROIs, mean number of COX4i1 puncta,
and mean number of COX4i1 puncta per ROI are presented in Figure 20. These
variables were used to identify any significant changes to TH+ cells within the medial
amygdaloid nucleus after rmTBI. The main factors analyzed were rmTBI and
testosterone supplementation. These data were statistically analyzed using a two-way
ANOVA statistical test, followed by a post-hoc multiple comparisons test. Since not all
experimental groups were present within the test (i.e. Sham-intact with immediate
testosterone supplementation), an interaction between the two main factors could not
be obtained.
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Figure 20. rmTBI Resulted in Increased Number of TH+ ROIs. This image
demonstrates (A) the mean number of TH+ ROIs, (B) COX4i1 puncta, and (C) number of
COX4i1 puncta per TH+ ROI within each experimental group. TH+ ROI represents TH+
mRNA clusters associated with the TH+ cell soma. rmTBI Cas I (immediate testosterone
treatment), rmTBI Cas 7 (7-day testosterone treatment). The two-way ANOVA statistical
test used for the mean number of TH+ ROIs demonstrated a significant main effect of
rmTBI (p=0.031) but did not demonstrate a main effect of testosterone supplementation
(p=0.24). The multiple comparisons analysis demonstrated a significant difference
between rmTBI with immediate testosterone treatment and Sham (p=0.046), as well as a
trend for significance between rmTBI with immediate testosterone treatment and Sham
(p=0.09), but did not demonstrate a difference between rmTBI with 7-day testosterone
treatment and Sham (p=0.90). The mean number of COX4i1 puncta were analyzed using
a two-way ANOVA statistical test, followed by a post-hoc multiple comparisons test. The
two-way ANOVA did not demonstrate a significant main effect of rmTBI or main effect of
testosterone treatment on the number of COX4i1 puncta present within the medial
amygdaloid nucleus. Multiple comparison analysis did not find any statistically significant
differences between experimental groups. Lastly, the mean number of COX4i1 puncta
per ROI within the medial amygdaloid nucleus was statistically analyzed using two-way
ANOVA statistical test, followed by a post-hoc multiple comparisons test. The two-way
ANOVA statistical test did not demonstrate a statistically significant main effect of rmTBI
or main effect of testosterone treatment on the mean number of COX4i1 puncta per ROI
present within the medial amygdaloid nucleus. The multiple comparisons analysis did not
demonstrate a significant difference between any experimental group. p= <0.05 = *. n=
3-6 per experimental group. Error bars represent means ± SEM.

CHAPTER SIX
DISCUSSION
The results from the behavioral experiments in the first specific aim of this thesis
identified both acute and persistent anxiety-like behaviors that resulted after rmTBI. The
effects of androgens on rmTBI through the removal and replacement of testosterone
were also determined in order to identify an optimal therapeutic time window for
testosterone replacement. The second specific aim of this thesis identified the medial
amygdaloid nucleus, a region with TH+ cells that also highly express androgen
receptors and looked at changes in expression of a marker of mitochondrial function to
determine how it was affected by rmTBI. This brain region is known to be involved in the
modulation of various fear and defensive behaviors, so it was of interest in the study of
anxiety-like behaviors after rmTBI.
The open field behavioral test utilized in the first specific aim is a well-known
assay used to assess anxiety-like behaviors in rats. When placed into a new
environment, rats will explore the novel area. Rats that exhibit more anxiety-like
behavior tend to stay out of the center of the open field due to increased risk of
predation and will spend more time near the walls on the outside of the arena. This wallhugging is known as ‘thigmotaxis’ behavior. Anxiety-like behaviors are identified in the
open field through the amount of time spent in the center of the arena, the latency in
leaving the center of the field after initial placement, behaviors such as freezing,
exploring, or grooming, as well as the number of times an animal explores the
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wall. Anxiety is a common behavioral symptom that develops due to rmTBI and can be
exacerbated. This thesis utilized a closed-headed CCI rmTBI model that has not before
been used to study anxiety-like behaviors at both early and persistent anxiety
timepoints. The effect of closed-headed CCI rmTBI was used in this study to model how
rmTBI affects the development of anxiety in individuals that sustain multiple mTBIs. This
model was used to characterize the effect of testosterone supplementation on anxiety
that develops after rmTBI.
Since suppression of circulating testosterone occurs after rmTBI, this thesis
addressed how hypogonadism could affect development of anxiety-like behaviors, or
even exacerbate these behaviors. One region of concern implicated in the development
of anxiety after rmTBI was the medial amygdaloid nucleus. This region contains
dopaminergic neurons that could be affected by rmTBI and hypogonadism. Gonadal
steroids are known to influence dopamine levels within various regions of the brain,
either through testosterone or aromatase conversion into estrogen, following injury or
induced neurotoxicity. The connectivity between regions involved in the anxiety
neurocircuitry, such as the amygdala and the BNST, could be impaired functionally due
to rmTBI. Overactivation, or an inability to attenuate activation, in the BNST after rmTBI
could lead to deleterious anxiety symptoms if left untreated. Current studies often
include only single mTBI and utilize different animal models77. Rodents have been used
in TBI research for decades now, in part due to less ethical concerns and better
economic advantages. Even more, rats have been increasingly utilized as animal
models in research due to the number of genetic tools available and the ease of working
with the animal78. Several species of rats have also been widely used in rmTBI

research
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. This study utilizes the repeat mTBI rat model to determine how multiple

mTBIs affect the development of anxiety that persists.
In order to better model the hypogonadal status of a rmTBI patient, castration
groups were used to reflect persistently suppressed testosterone levels for at least a
month after rmTBI. Additionally, the sham intact group was used to control for any
effects of anesthesia on gonadal steroid levels in each experimental group. Since it was
uncertain whether rmTBI animals would remain hypogonadal for at least one month
after rmTBI, castration was used to ensure persistent hypogonadism through the length
of this study. Testosterone can be suppressed in certain individuals for months or years
post-TBI, even after a single mTBI79. It is possible that testosterone will never return to
baseline levels in some of these individuals. The amount of testosterone in circulation
after subsequent testosterone supplementation can then be controlled and variability is
greatly reduced.
Animals that were exposed to rmTBI and castration exhibited increased anxietylike behaviors at PTD 28, although there were not any significant interactions between
rmTBI and castration for the anxiety-like behaviors observed at this timepoint. This
means that the separately calculated mean for rmTBI or the calculated mean for
castrated groups demonstrated a significant main effect on an anxiety-like behavior, but
there were no interactions found between rmTBI and castration. For example, both
rmTBI and castration demonstrated significant main effects separately on the time spent
freezing in the open field; however, there was not a significant interaction of the two
factors on time spent freezing. This means that rmTBI caused an increase in freezing
time and that castration caused an increase in freezing time when the groups were
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averaged, independently. In addition, both rmTBI and castration demonstrated
significant main effects separately on latency time to leave the inner square in the open
field. There was also a significant main effect of castration on time spent in the inner,
red-lined square. As far as time spent moving, there was not any significant interaction
or main effects of rmTBI or castration on amount of time spent moving in the open field
arena at PTD 28.
Expansive environments that without cover or refuge, such as a field without
trees or vegetation, are associated with increased risk of predation compared to an area
with cover or shelter. Experimentally, an open field behavioral test is utilized to assess
anxiety-like behaviors associated with this risk of predation, such as avoidance
behavior. In the open field arena, for example, increased anxiety-like behavior is
represented by an animal that leaves the center red-lined square more quickly upon
initial placement. When the animal remains closer to the walls and periphery of the
arena, this exhibits thigmotaxis behavior. Some animals in the rmTBI groups could have
had reduced levels of testosterone at PTD 28, which could then have resulted in
exacerbated anxiety-like behavior demonstrated by a reduced latency to leave the
center square.
The data presented in Figures 13 and 14 represent animals that were observed
for anxiety-like behaviors in the open field behavioral test at PTD 42. These figures
provide insight into the presence of anxiety-like behaviors beyond one month and the
effect of rmTBI as anxiety-like behaviors are maintained or could even worsen. This
experiment helped determine whether anxiety-like behaviors persisted, or were
exacerbated, beyond one-month post-rmTBI. The analysis for the anxiety-like behaviors
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observed at PTD 42 did not demonstrate any significant interactions between rmTBI
and castration. However, there were several significant main effects for the anxiety-like
behaviors. First, there was a significant main effect of rmTBI on mean number of red
lines crossed at PTD 42. There was also a significant main effect of rmTBI on time
spent in the inner square at PTD 42. However, there were no significant interactions or
main effects for number of wall explorations, time spent freezing, or time spent moving
at PTD 42 in the open field arena.
Each of these significantly reduced observational variables due to a main effect
of rmTBI demonstrated persistent anxiety-like behaviors that lasted for over a month
after the final rmTBI. Therefore, the anxiety-like behaviors measured by the open field
behavioral test in this experiment did not wane over time, or improve without treatment
or intervention, as suggested in previous studies68. Since the persistent anxiety-like
behaviors at PTD 42 did not improve without treatment, the next step was to determine
if testosterone supplementation could effectively reduce persistent anxiety-like
behaviors at this same timepoint.
The sample size for the first experimental design included a group number that
was approximately double the number calculated in the power analysis when effect size
was determined. Since a larger number was required for the subsequent testosterone
supplementation experiment, the group number had to be twice the size of the first
experiment to obtain sufficiently sized experimental groups. The problem with this large
sample size and an overpowered experiment is an increased risk of finding significance
for something that would not be meaningful clinically. In other words, overpowering an
experiment can lead to significant findings for a miniscule effect that does not mean
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anything. In addition, over-powered studies can mean wasted resources when it is not
necessary to include that many samples. However, in the context of this study, it was
necessary to add more animals to the experiment due to the combined groups that were
not separated until a later experiment. It is important to make note of these possible
risks when the data is interpreted for significant and meaningful results.
In order to study the effects of testosterone supplementation on persistent
anxiety-like behaviors, crystalized testosterone-filled capsules were implanted in rats at
PTD 35 and the open field behavioral test was utilized once again to determine changes
in anxiety-like behavior. Since the rats tested in the open field at PTD 42 had already
been subjected to the open field arena at PTD 28, a change score was calculated in
order to determine the change in frequency or duration of anxiety-like behaviors
between the two timepoints. A positive change score meant that the animal
demonstrated a larger number or longer duration of a behavior in the open field on PTD
42 compared to the first open field test on PTD 28. For example, a positive change
score of 5 in number of wall explorations for an animal meant that the animal
demonstrated 5 more wall explorations in the open field on PTD 42 than in the open
field on PTD 28. The results from this experiment, interestingly, did not demonstrate any
significant interactions or main effects of rmTBI, castration, or treatment on anxiety-like
behavior. This means that the one week of testosterone treatment did not effectively
reduce anxiety-like behaviors in animals at PTD 42. The change scores for all anxietylike behavioral variables were insignificant, which demonstrated that anxiety-like
behaviors were similar at PTD 42 compared to PTD 28.
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It is possible, however, that the testosterone supplemented only one week prior
to the open field experiment at PTD 42 did not allow the supplemented testosterone
enough time to initiate the intrinsic gonadal steroid-producing machinery within the
body. Testosterone treatment has been utilized for a longer duration and has proven to
be more therapeutic in some gonadectomized rodent models that study anxiety-like
behavior80. Other papers have reported that testosterone supplementation presented to
the circulation demonstrates more benefits after it has been present for greater than one
week81,82, or several months in older, hypogonadal men83. Another paper reported a
reduction in depressive symptoms and an improvement in overall mood in hypogonadal
men after testosterone supplementation at least one week after first treatment. This
improvement persisted for at least eight weeks with consistent treatment81. For these
reasons, it was important to see what testosterone supplementation introduced earlier
and for longer duration would do to these anxiety-like behaviors.
Alternatively, testosterone treatment given at PTD 35 could be too late to
completely eliminate persistent anxiety-like behaviors. Suppressed testosterone levels
within circulation of these individuals over time could increasingly exacerbate anxiety.
Individuals that experience persistently suppressed testosterone levels after rmTBI
could exhibit an increase in anxiety that is not effectively reversed by testosterone
provided after prolonged deprivation52.
Increased risk-taking behavior is a potential confound for the anxiety data at the
more persistent anxiety timepoint, which includes open field tests at PTD 28 and 42.
There is some debate within the literature on when this behavior begins after mTBI.
Some investigators suggest that anxiety-like behaviors begin to turn into more risk-

68
taking behaviors as early as 14 days or one month in mice , while others speculate that
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risk-taking behavior isn’t observed until at least several months following injury85. In
order to identify risk-taking behavior within this experimental rmTBI model, more specific
behavioral tests would be required to separate fear-related behaviors from risk-taking
behaviors.
The action of testosterone in male Long-Evans hooded rats could also be
affected due to pubertal changes that occur around the period in which animals receive
rmTBIs. If testosterone is required during puberty but is suppressed in animals after
rmTBI, then the body may not be as receptive to testosterone later in life. This provides
a plausible explanation for the lack of response to testosterone in the reduction of
anxiety-like behaviors at PTD 42. However, this explanation is unlikely for the
experiments conducted in this thesis due to the specific experimental design chosen.
Male Long-Evans hooded rats were approximately 60 days old when received and were
acclimated to their new environment for at least 3-7 days before they received any
rmTBI. Studies on male Long-Evans hooded rats have demonstrated that puberty ends
at approximately 42 days after birth, measured by preputial separation and copulation
behavior101,102. Therefore, the male Long-Evans hooded rats in this study are more
likely to have already gone through puberty, demonstrate proper receptiveness to
testosterone, and have normal, physiologic testosterone levels prior to rmTBI,
Immediate testosterone supplementation provided after the final rmTBI was
found more effective in reducing anxiety-like behaviors, compared to 7-day
supplementation. Since immediate supplementation reduced anxiety-like behaviors, the
next step was to determine whether immediate supplementation also facilitated proper
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function at a cellular level after rmTBI. Specifically, the goal of the second aim was to
determine whether immediate supplementation reduced mitochondrial dysfunction in the
medial amygdaloid nucleus, a brain region of interest.
The medial amygdaloid nucleus is an important region of interest for rmTBI and
anxiety, not only due to its potential link with anxiety-like symptomology, but for the
localization of ARs86,87 and respective response to testosterone after rmTBI. Proper
mitochondrial function is a requirement for all cells and must be regulated. Without
proper mitochondrial function within the cells, cell death can occur. The second specific
aim of this thesis was designed to identify changes in mitochondrial functioning as a
response to injury, as well as in response to testosterone treatment. The goal was to
measure COX4i1 expression within the medial amygdaloid nucleus as a marker of
mitochondrial dysfunction following injury, reflected by a decrease in COX4i1 mRNA
expression.
It was demonstrated that rmTBI caused an increase in the number of TH mRNA
expressed by the number of isolated cells in the medial amygdaloid nucleus, based on
visualization of ROIs in that brain region. If there was to be any change in the amount of
TH mRNA present within injured animals, the expectation would have been a decrease
in TH mRNA; however, what occurred was an increase in the amount of TH gene
expression after rmTBI, and specifically through multiple comparison analysis in the
rmTBI with immediate supplementation group. This study was one of the first within the
literature to clearly demonstrate the presence of TH+ cells in the medial amygdaloid
nucleus in rat through fluorescence in situ hybridization.
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This finding was particularly interesting due to the amount of controversy around
presence of TH+ cells in the medial amygdaloid nucleus in rat. The literature has
suggested that the presence of TH+ cells in the medial amygdaloid nucleus may be
species-specific. Some papers have reported that TH+ cells do not exist in larger
numbers, or in distinct populations, in the rat70,76. Instead, investigators have shown
TH+ cells in larger numbers in the male Syrian hamster70 and the prairie vole76, but
have claimed that TH+ cells are non-existent in the male rat. Studies in this thesis have
demonstrated a small number of TH+ ROIs within the medial amygdaloid nucleus
through fluorescence in situ hybridization. In the sham group, TH positive cells were not
obvious and the TH mRNA puncta could have been present more in the axons.
However, after rmTBI, there was a visible increase in the number of TH mRNA puncta
observed within the cell compared to TH mRNA puncta around the cells. This could be,
in part, why other investigators have not report distinct, clear TH+ cells within the medial
amygdaloid nucleus of rat. Clusters of red TH puncta were also denser in rmTBI
animals through the in situ experiments. This was determined through a qualitative
assessment of images taken of the rmTBI group compared to the sham group. Despite
not being as densely clustered, TH+ cells were still identifiable by TH mRNA puncta
within sham animals. Examples of TH+ cells within rmTBI and sham groups were
depicted in Figure 18. In order to corroborate these findings, the medial amygdaloid
nucleus was also investigated through the Allen Institute Brain Atlas72, which is an
online database that includes chromogenic in situ hybridization experiments and
provides images for many different mRNA sequences, including TH. This database
allowed for the identification of what appeared to be TH+ cells within the coronal
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sections of the medial amygdaloid nucleus of non-injured animals . This was, however,
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in the mouse brain, as they do not have this specific atlas available in rat. This provides
more support for the idea that TH+ cells are present within other species besides the
Syrian hamster or the prairie vole. It is important to note that, while investigators have
claimed to not find positive cells in the rat, much of the literature is older and the
sensitivity of techniques like the modern-day in situ hybridization experiments are much
more advanced than at that time.
As previously mentioned, the number of TH+ mRNA clusters were significantly
increased after rmTBI regardless of testosterone replacement. While the immediate
testosterone supplementation results show high variability and would require further
experiments to increase the group n, these data could oppose the behavioral findings
from specific aim 1. Immediate testosterone treatment in the first aim appeared to be
more effective in reducing anxiety-like behaviors compared to the 7-day treatment.
There are several possibilities regarding what is occurring within the medial amygdaloid
nucleus. First, it could be that immediate testosterone is not neurotherapeutic within the
medial amygdaloid nucleus at this PTD 14 timepoint. Since there was an increase in the
number of TH mRNA clusters after rmTBI, this poses the possibility that an increase in
TH mRNA clusters occurs as a pathophysiologic response to rmTBI. In this case, the 7day testosterone treatment could allow more time for the brain to adequately recover
before testosterone can act neurotherapeutically. The original hypothesis was that an
increase in COX4i1 mRNA clusters would be therapeutic. However, that is not what
resulted through this in situ hybridization experiment after rmTBI and testosterone
supplementation; there was no significant change in COX4i1 mRNA expression. It is
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currently unknown whether an increase in TH+ cells in the medial amygdaloid nucleus is
detrimental or therapeutic. Some studies have reported increased dopamine levels one
month after TBI in the frontal cortex and the striatum due to dysregulation in
dopaminergic neurotransmission89,90. This response is in stark contrast with the
decrease in dopamine expression that occurs in other brain regions, such as the
substantia nigra, after TBI68,91. Changes in dopamine expression after rmTBI are regionspecific and require further studies to help identify the mechanism in which
dopaminergic neurotransmission is affected within each brain region. However, for the
medial amygdaloid nucleus, this study demonstrates a significant increase in TH mRNA
expression that suggests increased dopamine expression after rmTBI. Secondly, it
could be that testosterone treatment does not affect the number of TH mRNA clusters
within this brain region at all, and the only difference seen is by rmTBI. In that scenario,
the compensatory increase in TH mRNA clusters could be declining by the PTD 14
timepoint and is not affected by treatment.
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Figure 21. TH+ Cell in the Medial Amygdaloid Nucleus. This image depicts a TH+
cell within the medial amygdaloid nucleus of a rmTBI-intact male rat at 20X
magnification. Red puncta represent TH, DAPI-blue.
These apparent “cells” may not actually be cell bodies but could instead be
axonal clusters or axon terminals surrounding a particular cell. Each of these
possibilities were contemplated after examination of previous immunohistochemistry
work on medial amygdala brain sections from a collaborator in the department and
within previous literature on the presence of mRNA trafficking down axons and toward
axon terminals. TH mRNA has been found within the axons of sympathetic neurons and
trafficking of this mRNA can be disrupted, which leads to impaired synthesis of
catecholamines, such as dopamine92,93. One downside to using in situ hybridization is
that only the mRNA within cells is fluorescently labeled and you are unable to see the
cell itself, so you cannot effectively localize where the mRNA is present within the cell.
The mRNA could then be within the nucleus, the cytoplasm, in the axon, or at the axon
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terminal of the pre-synaptic neuron. Further experiments are necessary to better
visualize where the TH mRNA is localized; however, the fact that this thesis may be one
of the first to detect TH mRNA in the rat at all is already novel in and of itself. The
localization of TH mRNA will help better determine the location of dopaminergic neurons
within the medial amygdaloid nucleus. TH is required to synthesize dopamine, and
rmTBI resulted in an increase in TH expression within this region. An increase in TH
mRNA within the cell body could be due to disruption in TH mRNA trafficking down the
axons after rmTBI, or it could be that TH gene expression is increased in dopaminergic
neurons after rmTBI. It is also possible that dopamine needs to be synthesized more
rapidly and secreted at the axon terminals surrounding a particular neuronal synapse
after rmTBI.
One hypothesis of this thesis was that TH expression in the medial amygdaloid
nucleus would be decreased following injury, as a result of mitochondrial dysfunction
and potential cell degeneration and death. Interestingly, TH expression levels,
qualitatively measured through number of TH+ ROIs, was increased in the medial
amygdaloid nucleus as a result of rmTBI. Changes in TH expression may be more
region-specific, where TH expression levels are increased after rmTBI in areas like the
frontal cortex94 and the substantia nigra95. Alternatively, other brain regions have
demonstrated decreased TH expression levels after rmTBI, such as the ventral
tegmental area96 and the median eminence97. The medial amygdaloid nucleus could be
an area that exhibits an increase in TH expression after rmTBI.
Rat brains in this study were collected 14 days after final rmTBI. It is possible that
compensatory responses are occurring rather than degeneration at this timepoint.
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Neuronal degeneration could take months to occur in certain brain regions after TBI or
within neurodegenerative disease, so there may be compensation that occurs earlier
which could then contribute to degenerative processes if left unchecked. There were
previous cohorts of rats that had gone for one or more months after rmTBI prior to
sacrifice and brain collection. The likelihood of observing degeneration is higher in those
brains compared to brains in this study that were collected at an earlier timepoint in this
study. In addition, increases in TH expression have been shown in other animal models
including hypothermal stress98, immobilization stress99, and foot shock stress100.
Contrary to the hypothesis, rmTBI did not affect COX4i1 expression in cells that
showed increased TH mRNA and suggests at this early timepoint there was no
degeneration due to mitochondrial dysfunction. There did not appear to be any
significance when comparing the five groups of interest for any of the three variables
investigated. The amount of time following injury, however, may not be long enough to
see true degeneration in the dopaminergic cells within the medial amygdaloid nucleus.
Instead, there could also be compensatory responses occurring within this region
following injury. It is possible that the TH+ cells within this area are not experiencing
mitochondrial dysfunction, or that any dysfunction is not yet evident due to
compensatory responses within the cells of this brain region. In addition, the n for a few
of the groups is not large and, with a few more animals added to each of those groups,
there may be more significant results for each of the COX4i1 in situ hybridization
variables.
Throughout the in situ hybridization process, optimization of the method was
required in order to obtain the best possible results from the tissue and to accurately
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detect the fluorescent label within that tissue. However, due to technical difficulties with
the in situ hybridization procedure and vulnerability with the amygdala brain region,
many samples could not be processed. This reduced the total number of viable samples
for the in situ hybridization experiments.

CHAPTER SEVEN
CONCLUSIONS
The goal of this thesis was to find answers to several important questions
surrounding rmTBI, changes in gonadal status, and anxiety. These goals included
identifying the effect of rmTBI on anxiety-like behaviors, determining if androgen
supplementation reduces anxiety-like behaviors after rmTBI, and testing whether
mitochondrial dysfunction within the medial amygdaloid nucleus is associated with
rmTBI and subsequent reduction of normal, physiologic testosterone levels.
The first specific aim focused on identifying anxiety-like behaviors in rats through
the open field behavioral test. Indeed, there were significant increases in various
anxiety-like behaviors at PTD 28 following the five-hit rmTBI experimental rat model.
This information helps provide insight into individuals experiencing multiple mTBIs and
experiencing anxiety as a prevalent symptom and could encourage seeking medical
attention sooner rather than later. The development of anxiety-like behaviors can persist
without proper diagnosis and treatment.
Animals were observed in the open field at PTD 42 to determine if anxiety-like
behaviors were reduced one week after testosterone supplementation began. The
results of this experiment were less clear. Significant changes in change score between
PTD 28 and PTD 42 were not seen in any of the anxiety-like behaviors observed, even
in animals that were given testosterone supplementation. Ideally, testosterone
supplementation would be neurotherapeutic and reduce anxiety-like behavior long after
77
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the final rmTBI. However, testosterone supplementation could require more than one
week before it demonstrates an effect, as the gonadal machinery in animals deficient for
an extended period of time. Testosterone supplementation provided immediately after
the final rmTBI reduced anxiety-like behavior, as shown by an increase in latency in
time to leave the center square, compared to the 7-day testosterone supplementation.
This further supports the idea that individuals could continue to experience persistent
anxiety and should be diagnosed as soon as possible. It also stresses the need for
continued development of neurotherapeutic therapies and treatments. The earlier those
therapies and treatments are provided to the individual, the better they will fare and
have a better health outcome.
The second specific aim was designed to identify whether the medial amygdaloid
nucleus, implicated in the anxiety neurocircuitry, could be exposed to oxidative stress
following rmTBI and result in increased anxiety-like behaviors. Interestingly,
mitochondrial function in this region was not impacted after rmTBI, as measured by
COX4i1 expression, at this particular timepoint. This could be because COX4i1 was the
only marker of mitochondrial function utilized in these experiments. It could also be that
COX4i1 expression levels measured by fluorescent in situ hybridization follow a more
complex pattern after rmTBI. The number of TH+ cells in the medial amygdaloid was
increased as a result of rmTBI. This result still requires further study, specifically looking
further into the presence of TH+ cells and TH expression within the medial amygdaloid
nucleus in the rat. Whether it be disrupted TH mRNA trafficking away from the cell body
after rmTBI that results in higher density of TH label in the cell body, or increased
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transcription of TH at the axon terminal that results in increased dopamine synthesis
and secretion, this novel finding generates even more questions.
The goal of this thesis was to test the effect of systemic testosterone
supplementation on markers of mitochondrial function in the medial amygdaloid
nucleus. Therefore, testing whether immediate or 7-day testosterone supplementation
could be neurotherapeutic within this brain region was important to future studies.
However, there did not appear to be any significant findings when comparing groups in
terms of COX4i1 mRNA expression levels. It is possible then, that testosterone acts in
another brain region and does not affect mitochondrial function in the medial
amygdaloid nucleus after rmTBI. Many other parts of the brain are being affected and
could contribute to the detrimental outcomes of increased anxiety. In addition, this study
looked at COX4i1 expression as a marker of mitochondrial function, but there may be
other markers that could provide more information about what occurs in the
mitochondria and in the cell that require further study.
Overall, it appears that androgens are neurotherapeutic in reducing multiple
anxiety-like behaviors expressed by rats within the open field behavioral test. The
androgens given systemically, however, did not cause a change in COX4i1 expression
levels within the medial amygdaloid nucleus at the earlier anxiety timepoint.
Alternatively, the behavioral data in this thesis suggests that the earlier the testosterone
supplementation, the better. While the immediate testosterone supplementation was not
as neurotherapeutic in the medial amygdaloid nucleus, as far as COX4i1 expression
levels and proper cell function, it likely acts within other regions important for emotional
regulation and processing in the brain.

CHAPTER EIGHT
FUTURE DIRECTIONS
The work in this thesis has resulted in several novel findings that promote
individuals with TBIs to seek medical attention sooner. It also encourages medical
professionals to use broader screening methods, such as testing for androgen levels in
individuals that sustained a single mTBI or rmTBI. Beyond the scope of this thesis,
many of these findings pose even more questions that require further experiments.
First, immediate testosterone treatment appeared to have the most significant effect on
anxiety-like behaviors, as demonstrated by time spent in the center square of the open
field at PTD 14. The next step would be to determine if immediate testosterone
treatment also helps reduce anxiety-like behaviors following injury at later timepoints,
either at one month or several months beyond injury. While immediate testosterone
treatment did not appear to have the same effect on mitochondrial function and TH
expression in the medial amygdaloid nucleus, it could still be acting in another brain
region to help reduce anxiety-like behaviors in rat. Therefore, further experiments would
be necessary to better grasp the location immediate testosterone treatment is most
neurotherapeutic.
Second, while the use of the open field behavioral test is a standard test to
measure anxiety-like behaviors, there are a variety of other behavioral tests that could
provide further insight into various behaviors related to anxiety. Behavioral tests such as
the elevated plus maze and the light-dark box have also been used within the anxiety
80
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Literature. Each of these tests can identify other behavioral phenomena that occur as a
result of rmTBI and could be essential to gain a better understanding of the
symptomology and potential for neurotherapeutic and/or neuroprotective gonadal
steroid treatments.
Third, further experiments are necessary to determine accurate localization of TH
mRNA in the medial amygdaloid nucleus after rmTBI. One such experiment could be to
utilize both fluorescence in situ hybridization + IHC on medial amygdaloid brain sections
to better visualize whether the TH mRNA is located in the cell body, cytoplasm, axon, or
another location in the cell. This would provide more information on where the TH
expression is after rmTBI compared to a sham animal, whether that be through
increased dopamine secretion as a compensatory response in this region or stuck
within the axon of a neuron due to disruption of trafficking after rmTBI.
Lastly, while the effect of testosterone treatment on proper mitochondrial function
in the medial amygdaloid nucleus did not appear to be significant, further in situ
hybridization experiments to detect AR expression within the medial amygdaloid
nucleus of rats could provide more insight into how testosterone interacts in this region.
Identifying where/if androgens bind in rat medial amygdaloid nucleus would allow for
greater understanding of changes in gonadal status following injury. Other papers
reported high levels of AR and TH colocalization in cells in the medial amygdaloid
nucleus of the Syrian hamster70. However, it has been reported that this population of
TH+ cells is species-specific, so it would be important to gain a better understanding of
AR colocalization in TH+ cells in the rat as well.
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